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A B S T R A C T
Background
This review is one of a suite of six Cochrane reviews looking at the primary medical management options for patients with chronic
rhinosinusitis.
Chronic rhinosinusitis is a common condition involving inflammation of the lining of the nose and paranasal sinuses. It is characterised
by nasal blockage and nasal discharge, facial pressure/pain and loss of sense of smell. The condition can occur with or without nasal
polyps. Oral corticosteroids are used to control the inflammatory response and improve symptoms.
Objectives
To assess the effects of oral corticosteroids compared with placebo/no intervention or other pharmacological interventions (intranasal
corticosteroids, antibiotics, antifungals) for chronic rhinosinusitis.
Search methods
The Cochrane ENT Information Specialist searched the ENT Trials Register; Central Register of Controlled Trials (CENTRAL 2015,
Issue 7); MEDLINE; EMBASE; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of
the search was 11 August 2015.
Selection criteria
Randomised controlled trials (RCTs) comparing a short course (up to 21 days) of oral corticosteroids with placebo or no treatment or
compared with other pharmacological interventions.
Data collection and analysis
We used the standard methodological procedures expected by Cochrane. Our primary outcomes were disease-specific health-related
quality of life (HRQL), patient-reported disease severity, and the adverse event of mood or behavioural disturbances. Secondary
outcomes included general HRQL, endoscopic nasal polyp score, computerised tomography (CT) scan score and the adverse events of
insomnia, gastrointestinal disturbances and osteoporosis. We used GRADE to assess the quality of the evidence for each outcome; this
is indicated in italics.
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Main results
We included eight RCTs (474 randomised participants), which compared oral corticosteroids with placebo or no intervention. All trials
only recruited adults with chronic rhinosinusitis with nasal polyps. All trials reported outcomes at two to three weeks, at the end of
the short-course oral steroid treatment period. Three trials additionally reported outcomes at three to six months. Two of these studies
prescribed intranasal steroids to patients in both arms of the trial at the end of the oral steroid treatment period.
Oral steroids versus placebo or no intervention
Disease-specific health-related quality of life was reported by one study. This study reported improved quality of life after treatment
(two to three weeks) in the group receiving oral steroids compared with the group who received placebo (standardised mean difference
(SMD) -1.24, 95% confidence interval (CI) -1.92 to -0.56, 40 participants, modified RSOM-31), which corresponds to a large effect
size. We assessed the evidence to be low quality (we are uncertain about the effect estimate; the true effect may be substantially different
from the estimate of the effect).
Disease severity as measured by patient-reported symptom scores was reported by two studies, which allowed the four key symptoms
used to define chronic rhinosinusitis (nasal blockage, nasal discharge, facial pressure, hyposmia) to be combined into one score. The
results at the end of treatment (two to three weeks) showed an improvement in patients receiving oral steroids compared to placebo,
both when presented as a mean final value (SMD -2.84, 95% CI -4.09 to -1.59, 22 participants) and as a change from baseline (SMD
-2.28, 95% CI -2.76 to -1.80, 114 participants). These correspond to large effect sizes but we assessed the evidence to be low quality.
One study (114 participants) followed patients for 10 weeks after the two-week treatment period. All patients in both arms received
intranasal steroids at the end of the oral steroid treatment period. The results showed that the initial results after treatment were not
sustained (SMD -0.22, 95% CI -0.59 to 0.15, 114 participants, percentage improvement from baseline). This corresponds to a small
effect size and we assessed the evidence to be low quality.
There was an increase in adverse events in people receiving orals steroids compared with placebo for gastrointestinal disturbances
(risk ratio (RR) 3.45, 95% CI 1.11 to 10.78; 187 participants; three studies) and insomnia (RR 3.63, 95% CI 1.10 to 11.95; 187
participants; three studies). There was no significant impact of oral steroids on mood disturbances at the dosage used in the included
study (risk ratio (RR) 2.50, 95% CI 0.55 to 11.41; 40 participants; one study). We assessed the evidence to be low quality due to the
lack of definitions of the adverse events and the small number of events or sample size, or both).
Other comparisons
No studies that compared short-course oral steroids with other treatment for chronic rhinosinusitis met the inclusion criteria.
Authors’ conclusions
At the end of the treatment course (two to three weeks) there is an improvement in health-related quality of life and symptom severity
in patients with chronic rhinosinusitis with nasal polyps taking oral corticosteroids compared with placebo or no treatment. The quality
of the evidence supporting this finding is low. At three to six months after the end of the oral steroid treatment period, there is little
or no improvement in health-related quality of life or symptom severity for patients taking an initial course of oral steroids compared
with placebo or no treatment.
The data on the adverse effects associated with short courses of oral corticosteroids indicate that there may be an increase in insomnia
and gastrointestinal disturbances but it is not clear whether there is an increase in mood disturbances. All of the adverse events results
are based on low quality evidence.
More research in this area, particularly research evaluating patients with chronic rhinosinusitis without nasal polyps, longer-term
outcomes and adverse effects, is required.
There is no evidence for oral steroids compared with other treatments.
P L A I N L A N G U A G E S U M M A R Y
Short-term oral corticosteroids compared with no treatment or other treatments for chronic rhinosinusitis
Review question
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We reviewed the evidence for the benefits and harms of a short course (typically up to 21 days) of corticosteroid given by mouth to
people with chronic rhinosinusitis compared with giving a placebo or no treatment, or another type of treatment.
Background
Chronic rhinosinusitis is a common condition that is defined as inflammation of the nose and paranasal sinuses (a group of air-filled
spaces behind the nose, eyes and cheeks). Patients with chronic rhinosinusitis experience at least two or more of the following symptoms
for at least 12 weeks: blocked nose, discharge from their nose or runny nose, pain or pressure in their face and/or a reduced sense of
smell (hyposmia). Some people will also have nasal polyps, which are grape-like swellings of the normal nasal lining inside the nasal
passage and sinuses.
Short courses of oral corticosteroids are a widely used treatment for chronic rhinosinusitis. They work by controlling the inflammatory
response and when polyps are present they rapidly reduce the size of the polyps to improve symptoms. The adverse effects of corticos-
teroids can include insomnia, mood changes and gastrointestinal changes (such as stomach pain, heartburn, diarrhoea, constipation,
nausea and vomiting). When given over the longer term, or through many repeated short courses, it is also possible to develop osteo-
porosis (fragile bones).
Study characteristics
This review includes evidence up to 11 August 2015. We included eight randomised controlled trials with a total of 474 participants.
All of the patients were adults who had chronic rhinosinusitis with nasal polyps. All of the studies followed patients until the end of
treatment (two to three weeks) and three studies (210 participants) followed up people for three to six months after the initial treatment
had ended. Five of the eight reports mentioned how the trial was funded. None of the funding sources were pharmaceutical companies.
Key results
At the end of a two- or three-week treatment course, people who took oral steroids may have had a better quality of life, less severe
symptoms and smaller nasal polyps than people who had placebo or did not receive any treatment. After three to six months, there was
little or no difference in quality of life, symptom severity or nasal polyps between the people who had oral steroids and the people who
had placebo or no intervention.
The people who took oral steroids may have had more gastrointestinal disturbances and insomnia than the people who had placebo or
no intervention. It is not clear if the people who took oral steroids had more mood disturbances than the people who had placebo or
no intervention.
Quality of the evidence
We judged the quality of the evidence for oral steroids plus intranasal steroids for adults with nasal polyps to be low (further research
is very likely to have an important impact on our confidence in the effect estimate and is likely to change the estimate), as the some of
the results are only from one or two studies, which do not have a lot of participants. Most of the trials do not have a high risk of bias,
but only people with nasal polyps were included in the review.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Short-course oral corticosteroids compared with placebo/ no treatment for chronic rhinosinusitis
Patient or population: chronic rhinosinusit is with nasal polyps
Intervention: short-course oral cort icosteroids
Comparison: placebo/ no treatment
Outcomes
of participants
(studies)
Relative effect
(95% CI)
Anticipated absolute effects∗ (95% CI) Quality What happens
Without oral steroids With oral steroids Difference
Disease-specif ic
health-related quality of
lif e measured by
severity score of RSOM-
31 (unclear range)
Follow-up: 2 weeks
of part icipants: 40
(1 RCT)
- Not est imable - The mean disease-
specif ic health-related
quality of lif e in the in-
tervent ion group was 1.
24 standard deviat ions
lower (1.92 lower to 0.
56 lower)
⊕⊕©©
LOW 1
A lower score indi-
cates reduced impair-
ment. Treatment ef -
fect in favour of short-
course oral steroids
• A SMD of 1.24 is
considered a large
ef fect size.
Disease severity, as
measured by pat ient-re-
ported symptom score,
measured by combin-
ing 4 individual symp-
toms
•
of part icipants: 22 (1
RCT)
•
of part icipants: 114
(1 RCT)
•
of part icipants: 114
(1 RCT)
- - - • The mean f inal
symptom score2 in the
intervent ion group at
17 days was 2.84
standard deviat ions
lower (4.00 lower to 1.
59 lower)
• The change f rom
baseline in symptom
score7 in the
intervent ion group at 2
weeks was 2.28
standard deviat ions
lower (2.76 lower to 1.
80 lower)
⊕⊕©©
LOW 3
⊕⊕©©
LOW 9
⊕⊕©©
LOW 10
A lower score indicates
milder symptoms in
favour of short-course
oral steroids
• SMDs of 2.84 and
2.28 are considered to
be large ef fect sizes.
Pat ients treated with
oral steroids probably
had much milder
symptoms at 2 to 3
weeks.
• A SMD of 0.22 is
considered to be a
small ef fect size.
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• The change f rom
baseline in symptoms
score7 at 3 months8
was 0.22 standard
deviat ions lower (0.59
lower to 0.15 higher)
Pat ients treated with
oral steroids and then
intranasal steroids
were probably not
much dif ferent in their
change in symptoms
f rom baseline to 3
months than the
pat ients who received
placebo and then
intranasal steroids.
Adverse events: signif i-
cant mood disturbance
Follow-up: 2 weeks
of part icipants: 40
(1 RCT)
RR 2.50
(0.55 to 11.41)
Study populat ion ⊕⊕©©
LOW 4
It is uncertain whether
there were more mood
disturbance adverse
events in the oral cort i-
costeroids group
100 per 1000 250 per 1000
(55 to 1000)
150 more per 1000
(45 fewer to 1041 more)
Health-related quality
of lif e, using generic
quality of lif e scores
This outcome was not reported in any of the studies
Adverse
events: gastrointest inal
disturbance
Follow-up: 3 months
of part icipants:187
(3 RCTs)
RR 3.45
(1.11 to 10.78)
Study populat ion ⊕⊕©©
LOW 5
There were more
gastrointest inal distur-
bance adverse events
in the oral cort icos-
teroids group47 per 1000 160 per 1000
(52 to 501)
114 more per 1000
(5 more to 455 more)
Adverse events: insom-
nia
Follow-up: 3 months
of part icipants:187
(3 RCTs)
RR 3.63
(1.10 to 11.95)
Study populat ion ⊕⊕©©
LOW 6
There were more in-
somnia adverse events
in the oral cort icos-
teroids group23 per 1000 84 per 1000
(26 to 278)
61 more per 1000
(2 more to 255 more)
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* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; OR: odds rat io; RCT: randomised controlled trial; RR: risk rat io; RSOM -31: Rhinosinusit is Outcome Measures-31; SM D: standard mean dif ference
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded to low quality due to lim itat ions in study methodology and imprecision. Only the disease severity scale of the
RSOM-31 was used (unknown validity of this subscale and the range of scores is unclear). One small study (n = 40),
which lacked information about the method of randomisat ion and allocat ion concealment. There is a also concern that the
magnitude of improvement is not sustained; one study that used a non-validated instrument reported smaller benef it at
three to six months than at two to three weeks for health-related quality of lif e.
2The individual symptoms measured were: nasal obstruct ion, nasal discharge, sense of smell and pressure over the sinuses.
Scores for the individual symptoms (0 to 10 visual analogue scale (VAS)) were summed to f ind the total score.The ef fect size
could be underest imated with this method.
3Downgraded to low quality due to imprecision. Results are f rom one very small study (n = 22) and the results were only
measured at the end of treatment (17 days). There is a concern that the magnitude of improvement is not sustained. The
outcome was not measured using a validated tool.
4Downgraded to low quality due to lim itat ions in study methodology and imprecision. One small study (n = 40), which lacked
information about the method of randomisat ion and allocat ion concealment. The def init ion of ’mood disturbance’ is not
provided in the paper. The results have large conf idence intervals.
5Downgraded to low quality due to inconsistency and imprecision. The term inology between the papers for this outcome
dif fered f rom ‘‘diarrhoea/ GI disturbance’’ to ‘‘gastrointest inal disturbance’’ to ‘‘ref lux and/ or gastric pain’’. A low number of
events were reported result ing in large conf idence intervals.
6Downgraded to low quality due to inconsistency and imprecision. The def init ion of ’insomnia’ is not provided in the papers.
A low number of events were reported result ing in large conf idence intervals.
7The individual symptoms measured were: blocked nose, rhinorrhoea, hyposmia and sinonasal pain. The results were
measured as individual symptoms on a seven-point Likert scale (0 = no symptoms) and presented as percentage change f rom
baseline for each symptom, which was averaged across the four symptoms to create an average change f rom baseline. The
ef fect size could be underest imated with this method.
8All pat ients in both groups received intranasal steroids at the end of the treatment period unt il the end of follow-up (12
weeks).
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9Downgraded to low quality due to lim itat ions in study methodology and imprecision. Results are f rom one small study (n =
117) with unclear randomisat ion and allocat ion concealment. The results were measured at the end of treatment (two weeks).
There is a concern that the results are not sustained. The outcome was not measured using a validated tool.
10Downgraded to low quality due to lim itat ions in study methodology and imprecision. Results are f rom one small study (n =
117) with unclear randomisat ion and allocat ion concealment. There is a small ef fect size with large conf idence intervals. The
outcome was not measured using a validated tool.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Chronic rhinosinusitis is defined as inflammation of the nose and
paranasal sinuses characterised by two or more symptoms, one of
whichmust be nasal blockage/obstruction/congestion or nasal dis-
charge (anterior/posterior nasal drip). The other possible symp-
toms include facial pain/pressure, reduction or loss of sense of
smell (in adults) or cough (in children). Symptomsmust have con-
tinued for at least 12 weeks. In addition, people must have either
mucosal changes within the ostiomeatal complex and/or sinuses as
evidenced by a computerised tomography (CT) scan and/or endo-
scopic signs of at least one of the following: nasal polyps, mucop-
urulent discharge primarily from middle meatus or oedema/mu-
cosal obstruction primarily in the middle meatus (EPOS 2012).
Chronic rhinosinusitis represents a common source of ill health;
11% of UK adults reported chronic rhinosinusitis symptoms in a
worldwide population study (Hastan 2011). Symptoms, including
nasal obstruction, nasal discharge, facial pain, anosmia and sleep
disturbance, have a major impact on quality of life, reportedly
greater in several domains of the SF-36 than angina or chronic res-
piratory disease (Gliklich 1995). Acute exacerbations, inadequate
symptom control and respiratory disease exacerbation are com-
mon. Complications are rare, but may include visual impairment
and intracranial infection.
Two major phenotypes of chronic rhinosinusitis have been iden-
tified based on the presence or absence of nasal polyps on ex-
amination. Nasal polyps are tumour-like hyperplastic swellings of
the nasal mucosa, most commonly originating from within the
ostiomeatal complex (Larsen 2004). Chronic rhinosinusitis with
nasal polyps (CRSwNP) is diagnosed when polyps are seen (on
direct or endoscopic examination) bilaterally in the middle mea-
tus. The acronym CRSsNP is used for the condition in which no
polyps are present.
Although the aetiology of chronic rhinosinusitis is not fully un-
derstood, it may involve abnormalities in the host response to ir-
ritants, commensal and pathogenic organisms and allergens, ob-
struction of sinus drainage pathways, abnormalities of normal mu-
cociliary function, loss of the normal mucosal barrier or infection.
Two typical profilesmay be observed with respect to inflammatory
mediators; in eosinophilic chronic rhinosinusitis, which is typi-
cally associated with nasal polyps, high levels of eosinophils, im-
munoglobulin E (IgE) and interleukin (IL)-5 may be found, while
in neutrophilic chronic rhinosinusitis, more often associated with
chronic rhinosinusitis without polyps, neutrophils predominate,
with elevated interferon (IFN) gamma, IL-8 and tumour necrosis
factor (TNF) (EPOS 2012).
While treatment decisions should be made based on an under-
standing of the patient’s chronic rhinosinusitis phenotype and
likely aetiology, in practice treatment may be initiated without
knowledge of the polyp status, particularly in primary care. This
review (and most of its companion reviews) consider patients with
and without polyps together in the initial evaluation of treatment
effects. However, subgroup analyses explore potential differences
between them (see below).
The most commonly used interventions for chronic rhinosinusitis
are used either topically (sprayed into the nose) or systemically (by
mouth) and include steroids, antibiotics and saline.
Description of the intervention
Short courses of oral steroids are widely used in medicine for a
variety of inflammatory conditions. In patients with chronic rhi-
nosinusitis they are often used with a view to gaining a rapid im-
provement in symptoms and to allow improved access for topi-
cally applied agents. They are typically given over a seven- to 21-
day period and may be at a fixed dose or incorporate a reducing
dose over the course. This strategy is thought to reduce the risk of
adverse effects (Mygind 1996). A wide spectrum of adverse events
are reported with systemic steroid usage (see Table 1); however,
data on the incidence in association with chronic rhinosinusitis are
lacking. While it is possible to extrapolate findings from trials in
other diseases, there is a risk that the incidence is disease-specific;
for example, a high incidence of avascular necrosis is seen with
high-dose steroid use in systemic lupus erythematosus, which is
in part attributed to the underlying disease process and severity
as well as the higher dosages prescribed in severe disease (Da Silva
2006).
Adverse effects associated with short-term oral steroid use are
said to include gastrointestinal disturbances, insomnia and altered
mental states. However, there are few or no published data on the
frequency of these effects when short-term courses are prescribed.
Adverse effects associated with long-term use of oral steroids are
also listed in Table 1.
How the intervention might work
Short courses of oral steroids are most often used in patients with
chronic rhinosinusitis with nasal polyps. The intention is to re-
duce the inflammation in order to produce a rapid reduction in the
size of the polyps, to improve symptoms and allow better penetra-
tion of topical treatments into the nasal cavity. They may be used
in a similar way for patients with chronic rhinosinusitis without
polyps, who have severe nasal obstruction or complete anosmia
(loss of sense of smell). The initial effect of treatment is expected
to be immediate. Any observed improvement may continue, es-
pecially if one effect of the intervention is to improve the bio-
availability of an adjunct treatment.
There is, however, a lack of evidence regarding the optimal treat-
ment regimen of oral steroids with respect to indication, dose and
duration. The optimum usage of steroids is clinically important as
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it may reduce the need for surgery by providing good symptomatic
control.
Why it is important to do this review
Short courses of oral steroids are widely used either alone or as
a form of add-on therapy in patients with chronic rhinosinusitis.
This review and a closely related new review of ’Short-course oral
steroids as an adjunct therapy for chronic rhinosinusitis’, Head
2016a, update and expand a previousCochrane review that looked
at this treatment in patients with polyps (Martinez-Devesa 2011).
This review seeks to establish the effectiveness of oral steroids
(compared to no treatment or placebo) and their relative effec-
tiveness compared to other commonly used agents for chronic
rhinosinusitis (such as intranasal corticosteroids). In contrast, the
companion review tries to establish the additional benefits (and
harms) of steroids when added on to existing therapies for chronic
rhinosinusitis.
This review is one of a suite of Cochrane reviews looking at com-
monmanagement options for patients with chronic rhinosinusitis
(Chong 2016a; Chong 2016b; Chong 2016c; Head 2016b; Head
2016a), and we use the same outcome measures across the reviews.
We have not included studies designed to evaluate interventions
in the immediate peri-surgical period, which are focused on as-
sessing the impact of the intervention on the surgical procedure
or on modifying the post-surgical results (preventing relapse).
O B J E C T I V E S
To assess the effects of oral corticosteroids compared with placebo/
no intervention or other pharmacological interventions (intranasal
corticosteroids, antibiotics, antifungals) for chronic rhinosinusitis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included studies with the following design characteristics:
• randomised controlled trials, including cluster-randomised
trials and quasi-randomised trials (cross-over trials were only to
be included if the data from the first phase were available); and
• patients were followed up for at least two weeks.
We excluded studies with the following design characteristics:
• randomised patients by side of nose (within-patient
controlled) because it is difficult to ensure that the effects of any
of the interventions considered can be localised; or
• perioperative studies, where the sole purpose of the study
was to investigate the effect of the intervention on surgical
outcome.
Types of participants
Patients with chronic rhinosinusitis, whether with polyps or with-
out polyps.
We excluded studies that included a majority of patients with:
• cystic fibrosis;
• allergic fungal sinusitis/eosinophilic fungal/mucinous
rhinosinusitis;
• aspirin-exacerbated respiratory disease;
• antrochoanal polyps (benign polyps originating from the
mucosa of the maxillary sinus);
• malignant polyps;
• primary ciliary dyskinesia;
• gross immunodeficiency (congenital or acquired);
• a history of surgery for nasal polyps within six weeks of
entry to the study.
Types of interventions
We included all short (see below) courses of oral steroids, regardless
of dose. This included:
• prednisone;
• prednisolone;
• methylprednisolone;
• hydrocortisone;
• cortisone acetate.
Short courses of oral steroids are defined as lasting up to, but not
exceeding, 21 days.
The main comparators were: placebo or no intervention.
The main comparison pairs were:
• oral steroids versus placebo or no treatment;
• oral steroids followed by intranasal corticosteroids versus
placebo or no treatment followed by intranasal corticosteroids.
Other possible comparison pairs included:
• oral steroids versus intranasal corticosteroids;
• oral steroids versus antibiotics;
• oral steroids versus antifungals.
This review is part of a larger series of six reviews of the treatment
of chronic rhinosinusitis.
• Intranasal steroids versus placebo or no intervention for
chronic rhinosinusitis (Chong 2016b).
• Different types of intranasal steroids for chronic
rhinosinusitis (Chong 2016a). This review compares different
classes, doses and delivery methods of intranasal corticosteroids
for chronic rhinosinusitis.
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• Short-course oral steroids alone for chronic rhinosinusitis
(this review). This review compares short-course oral steroids
alone with placebo or no intervention, or against other
pharmacological interventions such as antibiotics or nasal saline
irrigation.
• Short-course oral steroids as an adjunct therapy for chronic
rhinosinusitis (Head 2016a). This review compares oral steroids
where they have been used as add-on therapy to other treatments
for chronic rhinosinusitis (such as intranasal corticosteroids,
antibiotics or saline solution).
• Saline irrigation for chronic rhinosinusitis (Chong 2016c).
This review compares nasal saline irrigation for chronic
rhinosinusitis with both placebo/no intervention and with
intranasal corticosteroids or antibiotics.
• Systemic and topical antibiotics for chronic rhinosinusitis
(Head 2016b). This review compares both topical and systemic
antibiotics with placebo/no treatment, two different antibiotics
with each other and antibiotics with intranasal corticosteroids.
Types of outcome measures
We analysed the following outcomes in the review, but we did not
use them as a basis for including or excluding studies.
Both short-term (at the end of treatment) and long-term effects are
important therefore we evaluated outcomes at the end of treatment
or within three weeks thereof in addition to three to six months,
six to 12 months and more than 12 months. For adverse events,
we analysed data from the longest time periods.
Primary outcomes
• Health-related quality of life, using disease-specific health-
related quality of life scores, such as the Sino-Nasal Outcome
Test-22 (SNOT-22), Rhinosinusitis Outcome Measures-31
(RSOM-31) and SNOT-20.
• Disease severity, as measured by patient-reported symptom
score (such as the Chronic Sinusitis Survey (CSS) questionnaire
and visual analogue scales). In the absence of validated symptom
score data, patient-reported individual symptom scores were
reported for the following symptoms: nasal obstruction/
blockage/congestion, nasal discharge (rhinorrhoea), facial
pressure/pain, loss of sense of smell (adults), cough (children).
• Significant adverse effect: mood or behavioural
disturbances.
Secondary outcomes
• Health-related quality of life, using generic quality of life
scores, such as the SF-36, EQ-5D and other well-validated
instruments.
• Other adverse effects: gastrointestinal disturbances.
• Other adverse effects: insomnia.
• Other adverse effects: osteoporosis.
• Endoscopic score (depending on population, either nasal
polyps size score or endoscopy score, e.g. Lund-Mackay/Lund-
Kennedy).
• Computerised tomography (CT) scan score (e.g. Lund-
Mackay).
The adverse events that we collected from studies including one
of the various comparators listed above were the same as those
collected in the companion reviews assessing the effects of these
interventions as primary treatments.
Search methods for identification of studies
The Cochrane ENT Information Specialist conducted systematic
searches for randomised controlled trials and controlled clinical
trials. There were no language, publication year or publication
status restrictions. The date of the search was 11 August 2015.
Electronic searches
The Information Specialist searched:
• the Cochrane Register of Studies ENT Trials Register
(searched 11 August 2015);
• the Cochrane Central Register of Controlled Trials
(CENTRAL 2015, Issue 7);
• Ovid MEDLINE (1946 to July week 5 2015);
◦ Ovid MEDLINE (In-Process & Other Non-Indexed
Citations) (searched 11 August 2015);
◦ PubMed (as a top up to searches in Ovid MEDLINE)
(searched 11 August 2015);
• Ovid EMBASE (1974 to 2015 week 32);
• ClinicalTrials.gov, www.clinicaltrials.gov (search via the
Cochrane Register of Studies) (searched 11 August 2015);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (searched 11 August 2015);
• Google Scholar (searched 11 August 2015).
The Information Specialist modelled subject strategies for
databases on the search strategy designed for CENTRAL. Where
appropriate, theywere combined with subject strategy adaptations
of the highly sensitive search strategy designed by Cochrane for
identifying randomised controlled trials and controlled clinical tri-
als (as described in theCochraneHandbook for Systematic Reviews of
Interventions Version 5.1.0, Box 6.4.b. (Handbook 2011). Search
strategies for major databases including CENTRAL are provided
in Appendix 1.
Searching other resources
We scanned the reference lists of identified publications for addi-
tional trials and contacted trial authors where necessary. In addi-
tion, the Information Specialist searched PubMed, The Cochrane
Library and Google to retrieve existing systematic reviews relevant
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to this systematic review, so that we could scan their reference lists
for additional trials.
Data collection and analysis
Selection of studies
Two review authors independently screened all titles and abstracts
of the studies obtained from the database searches to identify po-
tentially relevant studies. Two review authors evaluated the full
text of each potentially relevant study to determine whether it met
the inclusion and exclusion criteria for this review.
We resolved any differences by discussion and consensus, with
the involvement of a third author for clinical and methodological
input where necessary.
Data extraction and management
Two review authors independently extracted data from each study
using a standardised data collection form (see Appendix 2).When-
ever a study had more than one publication, we retrieved all pub-
lications to ensure complete extraction of data. Where there were
discrepancies in the data extracted by different review authors, we
checked these against the original reports and resolved differences
by discussion and consensus, with the involvement of a third au-
thor or amethodologist where appropriate.We contacted the orig-
inal study authors for clarification or for missing data whenever
possible. If differences were found between publications of a study,
we contacted the original authors for clarification. We used data
from the main paper(s) if no further information was found.
We included key characteristics of the studies, such as study design,
setting, sample size, population and how outcomes were defined
or collected in the studies. In addition, we also collected baseline
information on prognostic factors or effect modifiers. For this
review, this included:
• presence or absence of nasal polyps;
• baseline nasal polyp score (where appropriate);
• whether the patient has had previous sinus surgery;
• number of previous courses of oral steroids.
For the outcomes of interest to the review, we extracted the find-
ings of the studies on an available case analysis basis; i.e. we in-
cluded data from all patients available at the time points based on
the treatment randomised whenever possible, irrespective of com-
pliance or whether patients had received the treatment as planned.
In addition to extracting pre-specified information about study
characteristics and aspects of methodology relevant to risk of bias,
we extracted the following summary statistics for each trial and
each outcome:
• For continuous data: the mean values, standard deviations
and number of patients for each treatment group. Where
endpoint data were not available, we extracted the values for
change from baseline. We analysed data from measurement
scales such as SNOT-22 and EQ-5D as continuous data.
• For binary data: the numbers of participants experiencing
an event and the number of patients assessed at the time point.
• For ordinal scale data: if the data appeared to be
approximately normally distributed or if the analysis that the
investigators performed suggested parametric tests were
appropriate, then we treated the outcome measures as
continuous data. Alternatively, if data were available, we
converted into binary data.
We prespecified the time points of interest for the outcomes in this
review. While studies may report data at multiple time points, we
only extracted the longest available data within the time points of
interest. For example, for ’medium-term’ follow-up periods, our
time pointwas defined as ’three to sixmonths’ post-randomisation.
If a study had reported data at three, four and six months, we only
extracted and analysed the data for the six-month follow-up.
Extracting data from figures
Where values for primary or secondary outcomes were shown as
figures within the paper we contacted the study authors to try to
obtain the raw values. When the raw values were not provided we
extracted information from the graphs using an online data ex-
traction tool (http://arohatgi.info/WebPlotDigitizer/app/), using
the best quality version of the relevant figures available.
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias of each
included study. We followed the guidance in the Cochrane Hand-
book for Systematic Reviews of Interventions (Handbook 2011), and
we used theCochrane ’Risk of bias’ tool.With this tool we assessed
the risk of bias as ’low’, ’high’ or ’unclear’ for each of the following
six domains:
• sequence generation;
• allocation concealment;
• blinding of participants, personnel and outcome assessment;
• incomplete outcome data;
• selective reporting;
• other sources of bias.
Measures of treatment effect
We summarised the effects of dichotomous outcomes (e.g. pro-
portion of patients with symptom resolution) as risk ratios (RR)
with CIs. For the key outcomes that we presented in the ’Sum-
mary of findings’ table, we also expressed the results as absolute
numbers based on the pooled results and compared to the assumed
risk. We had also planned to calculate the number needed to treat
to benefit (NNTB) using the pooled results where dichotomous
efficacy outcomes were available. The assumed baseline risk is typ-
ically either (a) the median of the risks of the control groups in
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the included studies, this being used to represent a ’medium risk
population’ or, alternatively, (b) the average risk of the control
groups in the included studies is used as the ’study population’
(Handbook 2011). If a large number of studies were available, and
where appropriate, we had planned also to present additional data
based on the assumed baseline risk in (c) a low-risk population
and (d) a high-risk population.
For continuous outcomes, we expressed treatment effects as amean
difference (MD) with standard deviation (SD) or as standardised
mean difference (SMD) if different scales were used to measure
the same outcome. We provided a clinical interpretation of the
SMD values.
Unit of analysis issues
This review did not use data from phase II of cross-over studies or
from studies where the patient was not the unit of randomisation,
i.e. studies where the side (right versus left) was randomised.
If we had found cluster-randomised trials, we would have analysed
these according to the methods in section 16.3.3 of the Cochrane
Handbook for Systematic Reviews of Interventions (Handbook
2011).
Dealing with missing data
We tried to contact study authors via email whenever the outcome
of interest was not reported, if the methods of the study suggested
that the outcome had been measured. We did the same if not all
data required for meta-analysis were reported, unless the missing
data were standard deviations. If standard deviation data were not
available, we approximated these using the standard estimation
methods from P values, standard errors or 95% CIs if these were
reported, as detailed in the Cochrane Handbook for Systematic Re-
views of Interventions (Handbook 2011). Where it was impossible
to estimate these, we contacted the study authors.
Apart from imputations for missing standard deviations, we con-
ducted no other imputations.However, we completed calculations
relating to disease severity (measured by patient-reported symp-
tom scores) as most of the data measured individual symptoms
rather than using validated instruments (see ’Imputing total symp-
tom scores’ below). We extracted and analysed data for all out-
comes using the available case analysis method.
Imputing total symptom scores
Where a paper did not present information for the total dis-
ease severity in terms of patient-reported symptom scores but did
present data for the results of individual symptoms, we used the
symptoms covering the important domains of the EPOS chronic
rhinosinusitis diagnosis criteria, EPOS 2012, to calculate a total
symptom score. The EPOS 2012 criteria for chronic rhinosinusitis
require at least two symptoms. One of the symptoms must be ei-
ther nasal blockage or nasal discharge; other symptoms can include
facial pressure/pain, loss of sense of smell (for adults) or cough (for
children). Where mean final values or changes from baseline were
presented in the paper for the individual symptoms we summed
these to calculate a ’total symptom score’. We calculated standard
deviations for the total symptom score as if the symptoms were in-
dependent, random variables that were normally distributed. We
acknowledge that there is likely to be a degree of correlation be-
tween the individual symptoms, however we used this process be-
cause the magnitude of correlation between the individual symp-
toms is not currently well understood (no evidence found). If the
correlation is high, the summation of variables as discrete vari-
ables is likely to give a conservative estimate of the total variance
of the summed final score. If the correlation is low, this method
of calculation will underestimate the standard deviation of the to-
tal score. However, the average patient-reported symptom scores
have a correlation coefficient of about 0.5; if this is also applica-
ble to chronic rhinosinusitis symptoms, the method used should
have minimal impact (Balk 2012). As this method of calculation
does not take into account weighting of different symptoms (no
evidence found), we downgraded all the disease severity outcomes
for lack of use of validated scales whenever this occurred.
Assessment of heterogeneity
We assessed clinical heterogeneity (which may be present even
in the absence of statistical heterogeneity) by examining the in-
cluded trials for potential differences between studies in the types
of participants recruited, interventions or controls used and the
outcomes measured.
We assessed statistical heterogeneity by visually inspecting the for-
est plots and by considering the Chi² test (with a significance level
set at P value < 0.10) and the I² statistic, which calculates the
percentage of variability that is due to heterogeneity rather than
chance, with I² values over 50% suggesting substantial heterogene-
ity (Handbook 2011).
Assessment of reporting biases
We assessed reporting bias as between-study publication bias and
within-study outcome reporting bias.
Outcome reporting bias (within-study reporting bias)
We assessed within-study reporting bias by comparing the out-
comes reported in the published report against the study protocol,
whenever this could be obtained. If the protocol was not available,
we compared the outcomes reported to those listed in themethods
section. If results were mentioned but not reported adequately in
a way that allowed analysis (e.g. the report only mentions whether
the results were statistically significant or not), bias in a meta-
analysis is likely to occur.We therefore sought further information
from the study authors. If no further information could be found,
we noted this as being a ’high’ risk of bias. Quite often there was
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insufficient information to judge the risk of bias; we noted this as
an ’unclear’ risk of bias (Handbook 2011).
Publication bias (between-study reporting bias)
We planned to assess funnel plots if sufficient trials (more than 10)
were available for an outcome. If we observed asymmetry of the
funnel plot, we would have conducted more formal investigation
using the methods proposed by Egger 1997.
Data synthesis
We conducted all meta-analyses using Review Manager 5.3
(RevMan 2014). For dichotomous data, we planned to analyse
treatment differences as a risk ratio (RR) calculated using theMan-
tel-Haenszel methods. We analysed time-to-event data using the
generic inverse variance method.
For continuous outcomes, if all the data were from the same scale,
we planned to poolmean values obtained at follow-upwith change
outcomes and report this as a MD. However, if the SMD had to
be used as an effect measure, we did not pool change and endpoint
data.
We used a fixed-effect model for data analysis, unless statistical
heterogeneity was substantial (> 50%). When statistical hetero-
geneity is low, random-effects versus fixed-effect methods yield
trivial differences in treatment effects. However, when statistical
heterogeneity is high, the random-effects method provides a more
conservative estimate of the difference. If statistical heterogeneity
was high, we conducted analysis using a random-effects model, if
the source of heterogeneity was unexplained.
Subgroup analysis and investigation of heterogeneity
We conducted some subgroup analyses regardless of whether sta-
tistical heterogeneity was observed, as these are widely suspected
to be potential effect modifiers. For this review, this included:
• phenotype of patients: whether patients had chronic
rhinosinusitis without nasal polyps, chronic rhinosinusitis with
nasal polyps, were a mixed group or the status of polyps is not
known or not reported. We undertook the subgroup analysis
because although there appears to be a considerable overlap
between the two forms of chronic rhinosinusitis with regards to
inflammatory profile, clinical presentation and effect of
treatment (Cho 2012; DeMarcantonio 2011; Ebbens 2010;
Fokkens 2007; Ragab 2004; Ragab 2010; van Drunen 2009),
there is some evidence pointing to differences in the respective
inflammatory profiles (Kern 2008; Keswani 2012; Tan 2011;
Tomassen 2011; Zhang 2008; Zhang 2009), and potentially
even differences in treatment outcome (Ebbens 2011).
We presented the main analyses of this review according to the
subgroups of phenotypes of chronic rhinosinusitis. We presented
all other subgroup analysis results in tables.
When studies had amixed group of patients, we analysed the study
as one of the subgroups (rather than as a mixed group) if more
than 80% of patients belonged to one category. For example, if
81% of patients had chronic rhinosinusitis without nasal polyps,
we analysed the study as that subgroup.
In addition to the subgroups above, we conducted the following
subgroup analyses in the presence of statistical heterogeneity:
• patient age (children versus adults);
• dose;
• duration of treatment.
Sensitivity analysis
We carried out sensitivity analyses to determine whether the find-
ings are robust to the decisions made in the course of identifying,
screening and analysing the trials. We planned to conduct sensi-
tivity analysis for the following factors, whenever possible:
• impact of model chosen: fixed-effect versus random-effects
model;
• risk of bias of included studies: excluding studies with high
risk of bias (we defined these as studies that have a high risk of
allocation concealment bias and a high risk of attrition bias
(overall loss to follow-up of 20%, differential follow-up
observed);
• how outcomes were measured: we investigated the impact
of including data where the validity of the measurement was
unclear.
If any of these investigations found a difference in the size of
the effect or heterogeneity, we mentioned this in the Effects of
interventions section.
GRADE and ’Summary of findings’ table
We used the GRADE approach to rate the overall quality
of evidence for each outcome using the GDT tool (http://
www.guidelinedevelopment.org/) for the main comparison pairs
listed in the Types of interventions section. The quality of evi-
dence reflects the extent to which we are confident that an esti-
mate of effect is correct and we applied this in the interpretation
of results. There are four possible ratings: ’high’, ’moderate’, ’low’
and ’very low’. A rating of ’high’ quality evidence implies that we
are confident in our estimate of effect and that further research is
very unlikely to change our confidence in the estimate of effect.
A rating of ’very low’ quality implies that any estimate of effect
obtained is very uncertain.
TheGRADE approach rates evidence fromRCTs that do not have
serious limitations as high quality. However, several factors can
lead to the downgrading of the evidence to moderate, low or very
low. The degree of downgrading is determined by the seriousness
of these factors:
• study limitations (risk of bias);
• inconsistency;
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• indirectness of evidence;
• imprecision;
• publication bias.
The ’Summary of findings’ table presents only the six top prior-
ity outcomes (disease-specific health-related quality of life, disease
severity score, generic quality of life and three adverse effects:mood
disturbances, gastrointestinal disturbance and insomnia). We did
not include the outcomes of endoscopic score or CT scan score,
or the adverse effect of osteoporosis in the ’Summary of findings’
table. Similarly, we did not present the results for the individual
symptoms in the ’Summary of findings’ table.
R E S U L T S
Description of studies
Results of the search
The searches retrieved a total of 2470 references after removal
of duplicates. We screened titles and abstracts and subsequently
removed 2424 studies. We assessed 46 full texts for eligibility. We
excluded 30 studies, with reasons. Thirteen papers are included
(eight studies). We identified three ongoing studies. There are no
studies awaiting assessment.
A flow chart of study retrieval and selection is provided in Figure
1.
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Figure 1. Process for sifting search results and selecting studies for inclusion.
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Included studies
We included eight published studies (13 papers) in the review
(Alobid 2014; Benitez 2006; Ecevit 2015; Hissaria 2006; Kapucu
2012; Kirtsreesakul 2012; Vaidyanathan 2011; Van Zele 2010).
See Characteristics of included studies.
There were five papers from one group in Spain (Alobid 2014;
Benitez 2006). After contacting the lead author of these papers
we clarified that there were two separate trials reported within the
different papers. We included the results from only two of these
papers: Alobid 2014 for the more recent trial and Benitez 2006
for the earlier trial. The additional papers either present identical
groups of patients, or results for subsets of patients.
The aim of the Ecevit 2015 study was to look at the impact of
short-course oral steroids on surgical outcomes. However, disease
severity was reported after oral steroid treatment had completed
but prior to surgery taking place and so we included the study in
this review.
Two of the trials had more than two study arms (Kapucu 2012;
Van Zele 2010). Kapucu 2012 was a four-arm study that com-
pared a short-course oral steroid, an intra-polyp steroid injection,
intranasal steroid treatment (triamcinolone acetonide spray 55µg,
two times daily with two puffs in both nostril cavities) and a con-
trol group who were not given any medication. The oral steroid
and the control group are included in this review. Van Zele 2010
was a three-arm study comparing oral corticosteroids (methylpred-
nisolone), placebo and antibiotics (doxycycline). Only the arm
comparing oral steroids with placebo is included in this review
although the results for the comparisons that include antibiotics
are reported in Head 2016b.
Design
All eight included studies are parallel-group, randomised con-
trolled trials (Alobid 2014; Benitez 2006; Ecevit 2015; Hissaria
2006; Kapucu 2012; Kirtsreesakul 2012; Vaidyanathan 2011; Van
Zele 2010). Three studies were unblinded and no steroid treat-
ment was provided in the control arm (Alobid 2014; Benitez 2006;
Kapucu 2012). Five studies stated that participants and health-
care professionals were blind to the treatment group (Ecevit 2015;
Hissaria 2006; Kirtsreesakul 2012; Vaidyanathan 2011; Van Zele
2010). A further discussion of blinding is made in the section
Blinding (performance bias and detection bias).
Setting
Four studies were conducted in ENTdepartments within hospitals
(Alobid 2014; Benitez 2006; Ecevit 2015, Van Zele 2010), two
in allergy outpatient clinics (Hissaria 2006; Kirtsreesakul 2012),
and one in a speciality clinic (Vaidyanathan 2011). The setting of
one study was unclear (Kapucu 2012).
Van Zele 2010 was a multicentre trial conducted on five sites in
four countries (Belgium, Germany, Holland and Australia). Five
studies were single-centre: two in the same unit in Spain (Alobid
2014; Benitez 2006), one inTurkey (Ecevit 2015), one inThailand
(Kirtsreesakul 2012), and one in Scotland (Vaidyanathan 2011).
The number of sites involved in the other studies are not known
although one was from Australia (Hissaria 2006), and the other
was Turkey (Kapucu 2012).
Participants and sample size
All of the published trials only included adults diagnosed with
chronic rhinosinusitis with nasal polyps. There were 474 partici-
pants included in the comparison of oral steroids with placebo or
no intervention.
The diagnostic criteria for inclusion into the trials varied by study.
Three studies did not refer to a minimum grade of nasal polyps
for inclusion (Hissaria 2006; Kapucu 2012; Kirtsreesakul 2012),
although Hissaria 2006 recruited only “symptomatic polyp pa-
tients”. Two studies included patients with moderate-to-severe bi-
lateral polyps (Alobid 2014; Vaidyanathan 2011). Alobid 2014
based their inclusion on the EPOS 2012 criteria (Appendix 3) and
Vaidyanathan 2011 was based on the European Position Paper on
Rhinosinusitis and Nasal Polyps 2007.
Three papers included amore severely affected or recalcitrant pop-
ulation (Benitez 2006; Ecevit 2015; Van Zele 2010). Benitez 2006
only included people with “severe” nasal polyps (mean score: 2.7
out of a possible 3 using the Lildholdt score), whereas it was re-
quired in the participants in Van Zele 2010 that either the nasal
polyps had recurred after surgical resection or were bilateral and
grades 3 or 4 in both nares using their five-point nasal polyp scor-
ing scale (Appendix 4). In Ecevit 2015, the inclusion criteria were
patients with moderate or severe nasal polyps who had not re-
sponded to a six-week course of fluticasone nasal drops (200 µg/
day). Out of 124 people treated with fluticasone, 23 met the in-
clusion criteria and were randomised to oral steroids or placebo.
Across all the included studies 67% of participants were male, in
keeping with the male preponderance seen in a recent epidemio-
logical study (Hopkins 2016; Philpott 2015). However, the mean
age of participants was 46 years, which is a decade lower than the
above referenced study; in fact it is notable that the mean age in
the control arm of Ecevit 2015 was 26.6 years (although this may
have been a reporting error) and the mean age for both arms in
Kapucu 2012 was 32.2 years. These participant groups may there-
fore not be fully representative of the overall chronic rhinosinusitis
population.
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Interventions and comparisons
All of the eight included studies provided results for a short course
of treatment (14 to 21 days) with oral steroids compared with
placebo or no treatment (Alobid 2014; Benitez 2006; Ecevit 2015;
Hissaria 2006; Kapucu 2012; Kirtsreesakul 2012; Vaidyanathan
2011; Van Zele 2010).
Four trials had washout periods prior to starting the trial (Alobid
2014; Benitez 2006; Kirtsreesakul 2012; Vaidyanathan 2011),
in which the patients received no steroids in the two weeks
(Vaidyanathan 2011), or four weeks prior to starting oral steroids
(Alobid 2014; Benitez 2006; Kirtsreesakul 2012).
Three different oral steroids were given within the trials: pred-
nisone (Alobid 2014; Benitez 2006), prednisolone (Ecevit 2015;
Hissaria 2006; Kirtsreesakul 2012; Vaidyanathan 2011), and
methylprednisolone (Kapucu 2012; Van Zele 2010). Both stud-
ies using prednisone started at 30 mg and reduced the dose over
the 14-day treatment course (reduced by 5 mg every two days)
(Alobid 2014; Benitez 2006). For prednisolone, Ecevit 2015 gave
a starting dose of 60 mg/day and then reduced this over the 17-
day treatment course. The other three studies gave a 14-day course
but with no reduction: Hissaria 2006 and Kirtsreesakul 2012 gave
50 mg/day whilst Vaidyanathan 2011 gave a lower dose of 25 mg/
day. Both studies using methylprednisolone reduced the dose over
the trial period. Kapucu 2012 gave oral methylprednisolone at a
varying dose depending on the weight of the patient (1 mg/kg/
day for three days then reduced by 8 mg/three days). The study
did not give details of the average duration of treatment. Van Zele
2010 gave 32 mg/day on days one to five, 16 mg/day on days 6 to
10 and 8 mg/day on days 11 to 20.
The comparator in three studies was no steroid treatment (no
placebo) (Alobid 2014; Benitez 2006; Kapucu 2012), placebo
tablets in four studies (Ecevit 2015; Hissaria 2006; Kirtsreesakul
2012; Vaidyanathan 2011), and placebo capsules in one study
(Van Zele 2010).
No information on any concurrent treatment was given in
four studies (Alobid 2014; Benitez 2006; Ecevit 2015; Kapucu
2012). Other medications were not permitted during the oral
steroid treatment stage in a further three (Kirtsreesakul 2012;
Vaidyanathan 2011; Van Zele 2010). Only Hissaria 2006 identi-
fied that participants were allowed to continue the use of regular
antihistamines (33% (13/40)), topical corticosteroids (55% (22/
40)), or both (it is unclear how many patients used both treat-
ments).
Three studies followed up patients beyond the end of the oral
steroid treatment phase (Kirtsreesakul 2012; Vaidyanathan 2011;
Van Zele 2010). Intranasal steroids were routinely prescribed to
patients in both treatment arms at the end of the oral steroid treat-
ment in two studies (Kirtsreesakul 2012; Vaidyanathan 2011).
In Vaidyanathan 2011, all participants received fluticasone propi-
onate nasal drops for eight weeks and then fluticasone propionate
nasal spray for a further 18weeks, making a total treatment time of
28 weeks (two weeks oral steroids or placebo followed by 26 weeks
of intranasal steroids). In Kirtsreesakul 2012, all patients received
mometasone furoate nasal spray for a further 10 weeks after initial
treatment. Although patients were followed up at 12 weeks in Van
Zele 2010, intranasal steroids were not routinely prescribed and
were only permitted as rescue medication two months after dosing
with the study medication.
Overall, the choice of oral corticosteroids used and the variety of
differing regimens reflect the variety seen in mainstream clinical
practice. Use of topical corticosteroids after the oral dose was in-
cluded as a definitive part of the patient pathway in two studies,
which reflects current practice.
Outcomes
One study did not report any of the primary or secondary out-
comes as defined in the methods section of this review (Kapucu
2012).
Disease-specific health-related quality of life (HRQL)
This was measured in two studies using different measure-
ment instruments (Hissaria 2006; Vaidyanathan 2011). Hissaria
2006 used the RSOM-31 questionnaire to measure HRQL af-
ter treatment (14 days), but modified the scoring system, us-
ing only the severity parameter but not the importance parame-
ter. Vaidyanathan 2011 used the Jupiter mini-Rhinoconjunctivi-
tis Quality of Life questionnaire (RQLQ) both immediately after
treatment (14 days) and at 26 weeks after treatment. This scale
is validated for patients with seasonal or perennial rhinoconjunc-
tivitis but the validity of this instrument is not known in chronic
rhinosinusitis patients and the scale is not clear within the paper.
Disease severity, as reported using patient-reported outcomes
Five studies provided information on patient-reported disease
severity at the end of treatment in terms of a combined score
or individual symptom scores, which could be combined into
a single score (Ecevit 2015; Hissaria 2006; Kirtsreesakul 2012;
Vaidyanathan 2011; Van Zele 2010). The symptoms measured,
the scales of measurement used and the way in which data were re-
ported varied greatly between studies. See Effects of interventions.
Three of the studies provided medium-term data on patient-re-
ported symptoms after a follow-up period of 10 to 12 weeks
(Kirtsreesakul 2012; Van Zele 2010), and 26 weeks (Vaidyanathan
2011).
Endoscopic score
Nasal polyp size was reported at the end of treatment in seven
studies (Alobid 2014; Benitez 2006; Ecevit 2015; Hissaria 2006;
Kirtsreesakul 2012; Vaidyanathan 2011; Van Zele 2010), and af-
ter a three- to six-month follow-up in three studies (Kirtsreesakul
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2012; Vaidyanathan 2011; Van Zele 2010). Hissaria 2006 re-
ported the estimated percentage reduction in polyp size using pairs
of photographs taken pre- and post-treatment. Five studies mea-
sured nasal polyps on a 0- to 3-point scale although the definitions
vary between categories (Alobid 2014; Benitez 2006; Ecevit 2015;
Kirtsreesakul 2012; Vaidyanathan 2011), and Van Zele 2010 used
a 0- to 4-point scale. The scales used are summarised in Appendix
4. There was a lack of information in the papers about themethods
used (e.g. was the value recorded the worst affected nostril or an
average of the two nostrils?), about the validation of the scales used
and about any precautions taken or calculation made to ensure
consistency between investigators.
Adverse events
Two studies made no mention of whether adverse events were
sought or identified in their papers (Alobid 2014; Benitez 2006).
Two studies reported that no adverse effects were observed: Ecevit
2015 stated that “Adverse effects were not observed in either
group”, whilst Kapucu 2012 stated that “No systemic or lo-
cal side effects of steroid treatment were seen in any patients”.
Vaidyanathan 2011 presented information about adverse events
well, but did not report any of the specific adverse effects of oral
steroids outcomes as pre-defined by this review, although adverse
events for intranasal steroid use after oral steroid treatment had
finished were reported. The remaining three studies provided clear
information about at least one of the adverse effects of interest
(Hissaria 2006; Kirtsreesakul 2012; Van Zele 2010).
Excluded studies
We excluded 30 studies after reviewing the full paper. Further de-
tails of the reasons for exclusion are summarised in Characteristics
of excluded studies. We identified 19 of these from the ex-
cluded papers list in previous version of the Cochrane review
(Martinez-Devesa 2011), and we found the reasons for exclusion
from the previous review to still be valid under the updated in-
clusion criteria developed for this review (Alobid 2005; Blomqvist
2001; Blomqvist 2009; Bonfils 1998; Bonfils 2003; Bonfils 2006;
Chi Chan 1996; Damm 1999; Hessler 2007; Jankowski 2003a;
Jankowski 2003b; Kroflic 2006; Lildholdt 1988; Lildholdt 1989;
Nores 2003; Ragab 2006; Rasp 2000; Sieskiewicz 2006; Stevens
2001).
Two papers reported RCTs comparing oral steroid treatment with
placebo or no treatment, but all study participants also received
concurrent treatmentwith antibiotics (Ozturk 2011), or intranasal
steroids (Bülbül 2013). These studies are included in theCochrane
review of short-course oral steroids as an adjunct for chronic rhi-
nosinusitis (Head 2016a). In addition, we identified one pro-
tocol for an ongoing RCT, which will aim to compare a short
course of oral steroids then intranasal steroids with intranasal
steroids alone. All patients in both arms will also receive antibi-
otics (NCT01676415). Further details for this study can be found
in the Cochrane review ’Short-course oral steroids as an adjunct
therapy for chronic rhinosinusitis’ (Head 2016a).
Of the remaining seven papers, Rupa 2010 included a population
of people with allergic fungal rhinosinusitis, which was out of
scope for this review. One study compared intranasal steroids with
oral steroids but intranasal steroid treatment was only given for 16
days (Reychler 2015). Six were either non-randomised studies or
commentaries on existing, included RCTs (Grammer 2013; Rasp
1997; Remer 2005; Sousa 2009; Tuncer 2003; van Camp 1994).
Ongoing studies
We identified three ongoing studies (Chi 2011; NCT00841802;
NCT02367118). All studies are investigating oral steroids com-
pared with either placebo or no treatment.Chi 2011 aims to com-
pare oral prednisone with placebo treatment for 20 days in pa-
tients with nasal polyps. The trial was registered in 2011 but no
further information was available despite attempts to contact the
author.NCT00841802 compares oral prednisone for 21 days with
placebo treatment in patients without nasal polyps. We contacted
the study authors and confirmed that the study was currently re-
cruiting participants but no results were currently available. The
other ongoing study, NCT02367118, aims to compare a five-day
course oral prednisone with no intervention, prior to surgery. The
study includes a mixture of patients with chronic rhinosinusitis
with and without nasal polyps and the authors confirmed that they
should be completing the study shortly, however no results were
available in time for this review. See Characteristics of ongoing
studies.
Risk of bias in included studies
The included studies were all randomised and controlled. Details
of the risk of bias for each study can be found in Figure 2. A ’Risk
of bias’ graph shows our judgements about each risk of bias item
presented as percentages across all included studies (Figure 3). In
general the reporting of the trials was not of a high quality.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Sequence generation
Six of the included studies reported that the participants had been
randomised to treatment groups but provided no further informa-
tion on themethods of sequence generation (Alobid 2014; Benitez
2006; Hissaria 2006; Kapucu 2012; Kirtsreesakul 2012; Van Zele
2010). The ratios for randomising into the separate groups were
provided for three of the studies: Alobid 2014 and Benitez 2006
randomised participants at a ratio of 3:1 into the intervention and
control arms respectively, whereas Kirtsreesakul 2012 randomised
at a ratio of 3:2 into the treatment and control arms respectively.
We assessed both of the remaining two studies to be at low risk
of bias with respect to randomisation. Ecevit 2015 randomised
participants in blocks of eight, whereas Vaidyanathan 2011 used
a computer-generated random allocation sequence to randomise
the trial, using block randomisation with a block size of four.
Allocation concealment
Six studies did not provide any information about allocation con-
cealment (Alobid 2014; Benitez 2006; Hissaria 2006; Kapucu
2012; Kirtsreesakul 2012; Van Zele 2010). For three trials the risk
of bias is increased as there was no blinding (Alobid 2014; Benitez
2006; Kapucu 2012).
We assessed two studies to be at low risk of allocation concealment
bias (Ecevit 2015; Vaidyanathan 2011).
Baseline characteristics
In three studies the baseline characteristics are poorly reported
(Alobid 2014; Benitez 2006; Kapucu 2012). The majority of the
information in Alobid 2014 relates to the overall cohort and base-
line characteristics for each group are not provided for age or gen-
der. Similarly, in Benitez 2006 some characteristics are only pre-
sented for the cohort as a whole (e.g. gender, aspirin sensitivity
and comorbidity of asthma). In Kapucu 2012, there is a lack of
information about the included population prior to treatment.
In addition, some of the studies do not report key information
for key potential effect modifiers that would be expected to be re-
ported. Four studies do not provide information about the severity
of the nasal polyps in the different groups at the start of the trial
(Alobid 2014; Benitez 2006; Kapucu 2012; Kirtsreesakul 2012).
Similarly, information about any previous surgery is not presented
in three papers (Benitez 2006; Ecevit 2015; Kirtsreesakul 2012).
In VanZele 2010 there was an imbalance in the number of aspirin-
intolerant patients in the baseline characteristics (oral steroids:
14.3%; placebo: 26.3%; antibiotics: 7.1%).
Blinding
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The participants and healthcare professionals in three studies were
not blinded to the treatment group (Alobid 2014; Benitez 2006;
Kapucu 2012). Since the main outcomes of interest in the review
are patient-reported, we considered the risk of bias for outcome
assessments to be high.
Van Zele 2010 states that the study was “double blinded” but pro-
vides no information about the dosing schedule of the three arms
within the trial (oral steroids, placebo and antibiotics) and what
precautions were taken to prevent the participants and healthcare
professionals from identifying the treatment arm to which they
had been allocated. There was no information about blinding of
outcome assessment in the paper.
The remaining four studies were all reported to be blinded and
provide good explanations of the methods used to prevent bias
from knowing the treatment arm to which participants had
been allocated (Ecevit 2015; Hissaria 2006; Kirtsreesakul 2012;
Vaidyanathan 2011).However, none of the studies make any com-
ment on the taste of the placebo tablet. Oral steroids are known
to have a distinctive bitter taste, which may be recognisable to pa-
tients who have previously received steroids, thus compromising
the blinding. It is unclear whether the taste of the interventions
was matched in these four studies and so we downgraded the risk
of bias to ’unclear’.
Incomplete outcome data
We assessed five studies to be at a low risk of attrition bias (Alobid
2014; Ecevit 2015; Hissaria 2006; Kapucu 2012; Kirtsreesakul
2012).One of these studies reported that all the patients completed
the trial and were included in the outcomes (Kapucu 2012). Four
other studies reported drop-out rates of less than5%(Alobid 2014;
Hissaria 2006; Ecevit 2015; Kirtsreesakul 2012).
In Benitez 2006, there was no mention of anyone who dropped
out of the trial or had to discontinue for any reason. However, it
was not stated within the paper how many patients were analysed
for each outcome and so we assessed the risk of bias for incomplete
outcomedata to be unclear.We also assessedVaidyanathan 2011 to
have an unclear risk of attrition bias; the study had a relatively large
drop-out rate (9/60 (15%)), although the reasons for these drop-
outs are well described. The results table gives different numbers
of participants included in each analysis, which are closer to the
number of patients available rather than patients randomised and
it is unclear why there is a discrepancy.
We assessed the risk of attrition bias in Van Zele 2010 as high.
Seven of the initial 47 patients dropped out of the study (14.9%)
and an intention-to-treat analysiswas conductedwith the last value
carried forward. However, all of the patients who dropped out
were from the placebo group: 7/19 (36.8%). The report implies
that they all dropped out after the treatment stage during follow-
up. This may have had an effect on the overall results and no
sensitivity analysis appears to have been completed to identify the
impact.
Selective reporting
We assessed Ecevit 2015 and Kirtsreesakul 2012 to be at a low risk
of selective reporting bias.
We assessed five studies to have anunclear risk of selective reporting
bias (Alobid 2014; Benitez 2006; Kapucu 2012; Vaidyanathan
2011; Van Zele 2010). Despite meeting the inclusion criteria
Kapucu 2012 did not report any of the primary or secondary
outcomes specified in this review. Two studies reported primary or
secondary outcomes (or both) but did not report any information
about whether adverse effects were experienced by any participant
within the study (Alobid 2014; Benitez 2006). Vaidyanathan 2011
did not report the methods for collecting data for adverse events
(other than biological assays). In Van Zele 2010, all outcomes in
themethods section have been reported in the full paper, although
many of them have been presented graphically, without providing
values at key time periods. The data were not reported in a way
that is sufficient to be included in the meta-analysis of this review.
We contacted the study authors but further information was not
provided.
We assessed Hissaria 2006 to be at high risk of reporting bias; the
nasoendoscopy findings were reported inconsistently within the
paper using differing criteria that had not been pre-specified in the
methods section. We were concerned that the cut-off points for
reporting could have been chosen after the results were available
to make the results look more favourable.
Protocols could be identified for two of the included studies
(Vaidyanathan 2011; Van Zele 2010). For Vaidyanathan 2011,
no differences were identified between the outcomes at the proto-
col stage and those reported in the paper. For Van Zele 2010, it
was difficult to judge whether there were differences between the
protocol and the full paper as the protocol was not very detailed.
We noted that the number of participants that the study aimed to
recruit was different from the number actually recruited (120 and
48 respectively).
Other potential sources of bias
Use of validated outcome measures
The validation of outcomes was one area that we identified at the
start of the review as an aspect that could lead to potential bias. If
an instrument is insensitive to measuring differences, this biases
the results to no difference. Six of the eight studies did not provide
information about the validation of any of the outcomes relevant
to this review (Alobid 2014; Benitez 2006; Ecevit 2015; Kapucu
2012; Kirtsreesakul 2012; Van Zele 2010). Furthermore, Van Zele
2010 also failed to provide information about the scale used for
measuring symptoms.
Vaidyanathan 2011 reported validation of the health-related qual-
ity of life measure (mini-RQLQ), although on further investiga-
tion it appears that the validation was not completed in a chronic
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rhinosinusitis population. The validation of other outcomes was
not mentioned. Hissaria 2006 provided references to the valida-
tion of the health-related quality of life outcomes (RSOM-31),
although they use a modified version and no information on how
this modification impacts the validation was made. For nasoen-
doscopy outcomes, the procedure to ensure reliability of measure-
ments was well presented.
Funding and conflicts of interest in trials
Three studies did not report information about funding of the
trials, or reported that no funding was provided (Ecevit 2015;
Hissaria 2006; Kapucu 2012). The remaining five studies reported
funding sources (Alobid 2014; Benitez 2006; Kirtsreesakul 2012;
Vaidyanathan 2011; Van Zele 2010). None of the studies were
explicitly funded by pharmaceutical companies with most of the
funding appearing to be from governmental or university grants.
Two studies did not provide information on any of the authors’ po-
tential conflicts of interest (Alobid 2014; Benitez 2006), and four
studies reported that the authors did not have any conflicts of inter-
est (Ecevit 2015; Kapucu 2012; Kirtsreesakul 2012; Vaidyanathan
2011).
Two studies noted that one or more authors had a potential con-
flict of interest (Hissaria 2006; Van Zele 2010). Hissaria 2006
reported one of the authors as receiving royalties from a medical
device company. Van Zele 2010 reported that one author had re-
ceived royalties from a medical device company and was a consul-
tant for another company (NeilMed). This author along with two
other authors received research grants from external bodies (Gar-
nett Passe and Rodney Williams Foundation, GlaxoSmithKline,
Stallergenes, European Union).
Effects of interventions
See: Summary of findings for the main comparison Short-
course oral corticosteroids compared with placebo/no treatment
for chronic rhinosinusitis
See also Summary of findings for the main comparison.
We analysed the pre-specified primary and secondary outcomes.
We included eight trials comprising 474 participants comparing
oral steroids with placebo in this review (Alobid 2014; Benitez
2006; Ecevit 2015; Hissaria 2006; Kapucu 2012; Kirtsreesakul
2012; Vaidyanathan 2011; Van Zele 2010), although one of these
studies did not include any of the pre-specified primary or sec-
ondary outcomes and so is not included in the results (Kapucu
2012). All of the studies followed up patients until the end of
treatment (14 to 21 days).
Three studies (224 participants) also followed up patients in both
arms for a further 10 to 26 weeks after treatment (Kirtsreesakul
2012; Vaidyanathan 2011; Van Zele 2010). Kirtsreesakul 2012
andVaidyanathan 2011 (177participants) gave patients fromboth
arms of the study intranasal corticosteroids after the end of oral
steroid treatment and followed up patients for a further 10 to 26
weeks. Van Zele 2010 (47 participants) did not routinely allow
intranasal corticosteroids after treatment with oral steroids but
followed up patients for 10 weeks after oral steroid treatment had
finished. The treatment of both arms with intranasal steroids, as
represented in Kirtsreesakul 2012 and Vaidyanathan 2011, more
accurately reflects current clinical practice than not providing any
treatment. However, the results for all three of the longer-term
trials are also analysed together and are presented below as three-
to six-month results.
Where the range of scales and values for minimal important
differences were unclear, we used the standardised mean differ-
ence (SMD) as a guide to estimate the effect sizes. As suggested
in the Cochrane Handbook for Systematic Reviews of Interventions
(Handbook 2011), we used standard rules of thumb in the inter-
pretation of effect sizes (SMD, or Cohen’s effect size of < 0.41 =
small, 0.40 to 0.70 = moderate, > 0.70 = large) (Cohen 1988).
Primary efficacy outcomes
1. Health-related quality of life, using disease-specific health-
related quality of life scores
After treatment (two to three weeks)
Two studies (98 participants) measured ’health-related qual-
ity of life’ using a disease-specific instrument (Hissaria 2006;
Vaidyanathan 2011). However, these are not fully validated in-
struments for patients with chronic rhinosinusitis:
• Hissaria 2006 used the RSOM-31 questionnaire (a
validated instrument) but modified the scoring system, using
only the severity parameter but not the importance parameter.
The study does not report the possible range of values that could
be obtained.
• Vaidyanathan 2011 used the mini-Rhinoconjunctivitis
Quality of Life Questionnaire (mRQLQ). This questionnaire
was developed to measure the quality of life for people with
seasonal or perennial rhinoconjunctivitis, and the validity for
chronic rhinosinusitis patients is unknown. It has at least three to
four items (out of 14) that are related to allergy but not
applicable to patients with chronic rhinosinusitis. In addition, it
does not include any items on sinonasal or facial pain and sense
of smell, which are symptoms included in the EPOS 2012
diagnostic criteria.
Therefore, we have not pooled the results of these studies but
they are plotted in Figure 4. The standardised mean difference
(SMD) observed in Hissaria 2006 was -1.24 (95% confidence
interval (CI) -1.92 to -0.56; 40 participants), whereas the SMD
in Vaidyanathan 2011 was -0.79 (95% CI -1.32 to -0.25; 58
participants) (Analysis 1.1). We considered both of these results
to be large effect sizes.
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Figure 4. Forest plot of comparison: 1 Oral steroids versus no treatment/placebo, outcome: 1.1 Disease-
specific health-related quality of life - no pooling (2 to 3 weeks).
Medium-term (three to six months)
Vaidyanathan 2011 also presented results for themini-RQLQdata
at 26 weeks. The scale is not clear within the paper. The SMD
was -0.59 (95% CI -1.16 to -0.02; 50 participants; one study)
(Analysis 1.2). We considered this result to be a moderate effect
size.
2. Disease severity, as measured by patient-reported
symptom score
None of the papers provided results for a patient-reported to-
tal symptom score validated in a chronic rhinosinusitis popula-
tion. Where available we combined the results for the individual
symptoms into a total score according to the methods section (see
Dealing with missing data). In order to be included in the analysis
the results needed to provide enough data to meet the EPOS 2012
diagnostic criteria (Appendix 3), which requires at least two symp-
toms to be present, one of which must be nasal blockage/obstruc-
tion/congestion or nasal discharge (anterior/posterior nasal drip),
with the other possible symptoms being facial pressure/pain, loss
of sense of smell (adults) or cough (children).
Four studies (232 participants) reported this outcome (Ecevit
2015;Hissaria 2006;Kirtsreesakul 2012;Vaidyanathan 2011), but
all used different measurements and presented results in different
ways.
• Ecevit 2015 (22 participants) asked patients to report
individual symptoms on a visual analogue scale (VAS) (0 to 10; 0
= no symptoms). Scores were given for the four symptoms
included in the EPOS 2012 definition (nasal obstruction, nasal
discharge, sense of smell and pressure over the sinuses), which
were combined to give a total mean final score with a possible
range of 0 to 40.
• Hissaria 2006 (40 participants) measured symptoms using
the nasal subscale of the RSOM-31, which measures six
symptoms: congestion, rhinorrhoea, sneezing, hyposmia,
postnasal discharge and thick nasal debris, all scored on a one- to
five-point VAS (1 = least severe, 5 = most severe). To obtain a
total value, the authors averaged the scores across all domains
and presented them graphically in the paper. The combined
results should, therefore, have been on a scale of one to five but
the results clearly show that one of the data points on the graph
is less than 1. We contacted the study authors to provide further
information but they did not respond. The nasal subscale of the
RSOM-31 represents three of the symptoms of the EPOS 2012
criteria. Facial pain/pressure was not reported.
• Kirtsreesakul 2012 (114 participants) asked patients to
report individual symptoms on a seven-point Likert scale (0 to 6;
0 = no symptoms, 6 = most severe). The results for each
symptom were presented graphically in the paper as percentage
change from baseline. The results for the four symptoms
representing the EPOS 2012 criteria (blocked nose, rhinorrhoea,
hyposmia and sinonasal pain) were averaged to create an average
change from baseline score.
• Vaidyanathan 2011 (57 participants) used the “total nasal
symptoms score”, which is calculated from the sum of scores for
nasal discharge, nasal blockage, nasal itch and sneezing, each
measured on a 0- to 3-point scale (total range 0 to 12; 0 = least
affected, 12 = most affected). The results include two of the
symptoms listed in the EPOS 2012 criteria (nasal blockage and
nasal discharge). Data for facial pain/pressure or loss of sense of
smell were not recorded. The validation status of the scale is
unknown and it is likely to be more specific for rhinitis
symptoms.
The results were presented in two different ways within the pa-
pers, either as ’mean final value’ (Ecevit 2015; Hissaria 2006;
Vaidyanathan 2011), or as ’change from baseline’ (Kirtsreesakul
2012). Results were only presented after treatment (at two to three
weeks) in both studies (Ecevit 2015; Hissaria 2006), and also as
medium-term results (three to six months after treatment) in two
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studies (Kirtsreesakul 2012; Vaidyanathan 2011).
We considered whether the results using different scales could be
pooled, but due to the differences in the individual symptoms in-
cluded in the scale, we did not consider pooling to be appropriate.
We plotted all results separately using SMD on the same forest
plot but did not present any totals (see Figure 5; Analysis 1.3).
Figure 5. Forest plot of comparison: 1 Oral steroids versus no treatment/placebo, outcome: 1.3 Disease
severity (patient-reported total symptom score).
After treatment (two to three weeks)
Mean final values
Three studies, with a total of 119 participants, presented results
as mean final values immediately after treatment (14 to 17 days)
(Ecevit 2015; Hissaria 2006; Vaidyanathan 2011). All of the re-
sults showed an improvement in the combined symptoms sever-
ity score for oral steroids compared with placebo at the end of
treatment, with the largest effect being observed in Ecevit 2015
(SMD -2.84, 95% CI -4.08 to -1.59, 22 participants), followed
by Hissaria 2006 (SMD -1.59, 95% CI -2.31 to -0.87, 40 par-
ticipants) and Vaidyanathan 2011 (SMD -0.79, 95% CI -1.33 to
-0.25, 57 participants) (Analysis 1.3). All of these SMD values
corresponded to large effect sizes.
We observed a variation in the results for symptom severity be-
tween the trials. This may have been due to:
• differences in the outcome measurement being used in each
scale - different individual symptoms were measured in each case
and the validity and sensitivity of the scales to measure this
outcome are unknown;
• differences in the included populations within the studies -
participants in Ecevit 2015 were more severely affected at
baseline according to the diagnostic criteria;
• differences in the interventions provided - Ecevit 2015
provided oral steroids at a higher dose than Hissaria 2006 or
Vaidyanathan 2011.
Change from baseline
Kirtsreesakul 2012 (114 participants) showed a larger average per-
centage improvement in total symptom score for the oral steroids
group compared with placebo at the end of treatment (14 days)
(SMD -2.28, 95% CI -2.76 to -1.80) (Analysis 1.3). This corre-
sponds to a large effect size.
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Medium-term (three to six months)
Mean final value
Vaidyanathan 2011 (51 participants) provided results at 26 weeks
after the end of oral steroid treatment, where both arms of the trial
had been given intranasal steroids after 21 days (when the short
course of oral steroids ended). The result for total nasal symptom
score was SMD -0.43 (95% CI -0.99 to 0.12) (Analysis 1.3). This
corresponds to a moderate effect size.
Change from baseline
Kirtsreesakul 2012 (114 participants) provided data that allowed
the calculation of three- to six-month results for percentage change
in total symptoms score from baseline, 10 weeks after completing
the oral steroid treatment, where both arms of the trial had been
given intranasal steroid therapy from two weeks (i.e. at the end
of the oral steroid treatment period). The result for percentage
change from baseline was SMD -0.22 (95% CI -0.59 to 0.15)
(Analysis 1.3). This corresponds to a small effect size.
Individual symptom scores
Data for patient-reported individual symptoms were presented
in three papers (Ecevit 2015; Kirtsreesakul 2012; Vaidyanathan
2011). These papers used different measurement scales for the
rating of symptoms.
• Ecevit 2015 (22 participants) asked participants to rank
symptoms on a visual analogue scale of 0 to 10 (0 = no
complaint, 10 = most annoying). The paper presented the final
mean values.
• Kirtsreesakul 2012 (114 participants) asked participants to
rate symptoms using a seven-point Likert scale (0 to 6, 0 = no
symptoms, 6 = severe symptoms). The paper presented results
graphically in figures for percentage improvement from baseline
for each symptom. We extracted the data from graphs. Data were
presented for after treatment (two weeks) and also at 12 weeks
after both groups had received intranasal steroids.
• In Vaidyanathan 2011 the only individual symptom for
which data were extractable was hyposmia, which was measured
by patients on a 0 to 100 mm hyposmia visual analogue scale. It
is not clearly described within the paper but it is inferred from
the discussion that a higher score relates to greater severity of
smell loss.
Although Alobid 2014 measured loss of sense of smell using the
Barcelona Smell Test-24 score, the results were presented for all
patients, control group, patients with asthma and patients without
asthma and so it was not possible to include these results.
Nasal obstruction/congestion/blockage
Final value
One study (22 participants) presented data for the mean final
value of the nasal obstruction symptom score (measured on a 0 to
10 VAS, 0 = no nasal blockage) for oral steroids compared with
placebo at the end of the 17-day treatment course (mean difference
(MD) -4.50, 95% CI -6.42 to -2.58) (Ecevit 2015) (Analysis 1.4).
Change from baseline
One study (114 participants) presented data for percentage change
in nasal blockage (measured on a seven-point Likert scale, 0 =
no symptoms) for oral steroid treatment compared with placebo
after a 14-day treatment course (MD -38.02, 95% CI -48.16 to
-27.88; 114 participants) and at three months after oral steroid
treatment had finished when all patients in both study arms had
received intranasal steroids for 10 weeks (MD 0.90, 95% CI -8.97
to 10.77) (Kirtsreesakul 2012) (Analysis 1.5).
Nasal discharge
Final value
One study (22 participants) presented data for themean final value
of nasal discharge symptom score (measured on a 0 to 10 VAS, 0
= no nasal discharge) for oral steroids compared with placebo at
the end of a 17-day treatment course (MD -4.70, 95% CI -6.79
to -2.61) (Ecevit 2015) (Analysis 1.6).
Change from baseline
One study (114 participants) presented data for percentage change
in rhinorrhoea (measured on a seven-point Likert scale, 0 = no
symptoms) for oral steroid treatment compared with placebo after
a 14-day treatment course (MD -55.57, 95%CI -69.23 to -41.91)
and at three months after oral steroid treatment had finished when
all patients in both study arms had received intranasal steroids for
10 weeks (MD -1.83, 95% CI -13.46 to 9.81; 114 participants)
(Kirtsreesakul 2012) (Analysis 1.7). Rhinorrhoea was used in pref-
erence to the individual symptom of postnasal drip, which was
also reported in the paper.
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Facial pain/pressure
Final value
One study (22 participants) presented data for themean final value
of facial pressure symptom score (measured on a 0 to 10 VAS, 0 =
no facial pressure) for oral steroids compared with placebo at the
end of a 17-day treatment course (MD -3.70, 95% CI -6.02 to -
1.38) (Ecevit 2015) (Analysis 1.8). The symptom of facial pressure
was used in preference to the individual symptom of headache.
Change from baseline
One study (114 participants) presented data for percentage change
in sinonasal pain (measured on a seven-point Likert scale, 0 = no
symptoms) for oral steroid treatment compared with placebo after
a 14-day treatment course (MD -30.66, 95%CI -46.28 to -15.04)
and at three months after oral steroid treatment had finished when
all patients in both study arms had received intranasal steroids
for 10 weeks (MD 0.60, 95% CI -12.56 to 13.76) (Kirtsreesakul
2012) (Analysis 1.9). Rhinorrhoea was used in preference to the
individual symptom of postnasal drip, which was also reported in
the paper.
Loss of sense of smell
Final value
Two studies (80 participants) presented data for the mean final
value of loss of sense of smell (Ecevit 2015; Vaidyanathan 2011).
Ecevit 2015 measured smell on a 0 to 10 scale (0 = no loss of
sense of smell) and Vaidyanathan 2011 measured this on a 0 to
100 mm hyposmia VAS (0 = no loss of sense of smell), which we
subsequently scaled to represent a 0 to 10 scale. The result for oral
steroids compared with placebo at the end of treatment (14 to 17
days) was MD -2.79 (95%CI -4.11 to -1.47). Vaidyanathan 2011
also presented results 26 weeks after the end of treatment when
patients in both arms had received intranasal steroids (MD -1.20,
95% CI -2.68 to 0.28) (Analysis 1.10).
Change from baseline
One study (114 participants) presented data for percentage change
in hyposmia (measured on a seven-point Likert scale, 0 = no symp-
toms) for oral steroid treatment compared with placebo after a 14-
day treatment course (MD -44.35, 95% CI -57.31 to -31.39) and
at three months after oral steroid treatment had finished when all
patients in both study arms had received intranasal steroids for 10
weeks (MD -15.05, 95%CI -29.69 to -0.41) (Kirtsreesakul 2012)
(Analysis 1.11).
None of the results for individual symptoms are presented in the
GRADE ’Summary of findings’ table as we considered it to be re-
presenting information that was already included in the disease
severity score and, as such, not considered to be a priority outcome.
3. Significant adverse effect: mood or behavioural
disturbances
One study (40 participants) reported mood disturbances as an
adverse event (Hissaria 2006). This study found that there were
no differences between the oral steroid and the placebo group after
the two-week treatment course (5/20 oral steroids, 0/20 placebo)
(risk ratio (RR) 2.50, 95% CI 0.55 to 11.41) (Analysis 1.12).
Secondary efficacy outcomes
1. Health-related quality of life, using generic quality of life
scores, such as the SF-36, EQ-5D and other well-validated
instruments
None of the studies reported this as an outcome.
2. Other adverse effects: gastrointestinal disturbances
We analysed together the short-term ’after treatment’ results (two
to three weeks) and the medium-term ’three to six months’ results
for gastrointestinal disturbances. Three studies (187 participants)
reported gastrointestinal disturbances as an adverse event (Hissaria
2006; Kirtsreesakul 2012; Van Zele 2010). Hissaria 2006 reported
adverse events after the treatment course had ended (two weeks),
whereas Kirtsreesakul 2012 and Van Zele 2010 reported adverse
events at 12 weeks. We meta-analysed the results and there was an
increase in gastrointestinal disturbance in the oral steroid group
compared with placebo (15/101, 4/86) (RR 3.45, 95% CI 1.11
to 10.78) (Analysis 1.13).
3. Other adverse effects: insomnia
Three studies (187 participants) reported insomnia as an adverse
event (Hissaria 2006;Kirtsreesakul 2012;VanZele 2010).Hissaria
2006 reported adverse events after the treatment course had ended
(two weeks), whereas Kirtsreesakul 2012 and Van Zele 2010 re-
ported adverse events at 12 weeks. We meta-analysed the results
and there was an increase in insomnia in the oral steroid group
compared with placebo (10/101, 2/86) (RR 3.63, 95% CI 1.10
to 11.95) (Analysis 1.14).
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4. Adverse effects: osteoporosis
None of the studies reported this as an outcome.
5. Endoscopic score (polyps size for chronic rhinosinusitis
with polyps population, or overall endoscopy score for
chronic rhinosinusitis without polyps population)
Five studies measured nasal polyps on a zero- to three-point scale,
although the wording used to describe each of the categories is not
consistent between the studies (Appendix 4) (Alobid 2014; Benitez
2006; Ecevit 2015; Kirtsreesakul 2012; Vaidyanathan 2011). After
reviewing the scales we agreed to analyse the results of the studies
together as we thought the definitions between the categories to
be roughly equivalent.
After treatment (two to three weeks)
Final value
Four studies (253 patients) reported the total nasal polyp score at
the end of treatment (Alobid 2014; Benitez 2006; Ecevit 2015;
Vaidyanathan 2011). All of the studies used the four-point (0 to 3)
scale for the measurement of polyps severity. Vaidyanathan 2011
summed the scores for each nostril together to give a total scale
of 0 to 6. We have divided these results by two to provide the
average polyp score for both nostrils on a scale of 0 to 3, to be
consistent with the other studies. It is unclear in the other three
papers whether the result refers to the polyp grade in the worst
affected nostril or an average of the polyp grade by nostril (Alobid
2014; Benitez 2006; Ecevit 2015). The results showed that there
was a reduction in nasal polyp score for oral steroids compared
with placebo/no treatment at two weeks (MD -0.76, 95% CI -
0.92 to -0.61, 253 participants) (Analysis 1.15). This observed
mean difference corresponds to large effect size (SMD of -1.21).
There is moderate heterogeneity within themean final nasal polyp
size results as presented above (heterogeneity: Chi² = 7.20, df = 3
(P value = 0.07); I² = 58%). When Vaidyanathan 2011 is removed
from the analysis, the heterogeneity is reduced.Thismay have been
due to differences in the methods of assessing the nasal polyps.
Change from baseline
Van Zele 2010 measured the nasal polyps score on a five-point
scale (0 to 4), which was used for each nostril and then summed
to get an overall nasal polyp score. The paper presented the results
graphically as change from baseline polyps score, however data on
the variance of the point estimates were not available for this study
and it was not possible to impute them from other studies due to
differences in the scale, so it was not included in themeta-analysis.
Two studies (146 patients) reported the percentage improvement
from baseline values at the end of treatment (Hissaria 2006;
Kirtsreesakul 2012).Kirtsreesakul 2012measured the polyps grade
using a 0 to 3 scale, whereas Hissaria 2006 reported the estimated
percentage reduction inpolyp size usingpairs of photographs taken
pre- and post-treatment. As these ways of measuring polyps were
different, we analysed the data using standardised mean difference
to report the results. The results showed that there was a larger
change from baseline in the size of nasal polyps in the oral steroids
group compared with the control group after treatment (two to
three weeks) (SMD -1.77, 95% CI -2.16 to -1.38). This corre-
sponds to a large effect size (Analysis 1.16).
Medium-term (three to six months)
Final value
One study (50 patients) provided results for final mean value of
nasal polyps score for oral steroids compared with placebo, 26
weeks after the initial treatment period with both study arms re-
ceiving treatment with intranasal steroids (Vaidyanathan 2011).
The mean difference in nasal polyps at 26 weeks was -0.25 (95%
CI -0.62 to 0.12, 50 participants) on a 0- to 3-point scale (Analysis
1.15). The observed mean difference corresponds to a small effect
size (SMD of 0.36).
Change from baseline
One study measured results at three months from the start of the
trial when all patients in both study arms had received intranasal
steroids for 10 weeks (Kirtsreesakul 2012). The results for the oral
steroid arm compared to the placebo arm were SMD -0.52 (95%
CI -0.90 to -0.14) (Analysis 1.16). This corresponds to a moderate
effect size.
The results for endoscopic score are not presented in the ’Summary
of findings’ table as we did not consider it to be a priority outcome.
6. Computerised tomography (CT) scan score
None of the studies reported this as an outcome.
D I S C U S S I O N
Summary of main results
This review includes eight trials comparing the effectiveness
of short-course oral steroids with placebo or no treatment in
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adults with chronic rhinosinusitis with nasal polyps (Summary of
findings for the main comparison).
There was low quality evidence of an improvement in disease-
specific health-related quality of life after treatment (two to three
weeks) with oral corticosteroids compared with placebo or no
treatment. There is a concern that the magnitude of the improve-
ment is not sustained.
There was low quality evidence of an improvement in disease sever-
ity (lower symptom score) in the oral steroids group compared
with the control group at the end of the steroid treatment (two
to three weeks). At three months, when all patients had received
intranasal steroids after the treatment period had ended, there was
low quality evidence that there was no difference in the change
from baseline in symptom severity between the oral steroids and
control groups.
There was low quality evidence of an increase in insomnia and
gastrointestinal disturbances in the oral steroids group compared
with the control group. It is unclear whether there is a difference
between the intervention and control groups for mood distur-
bances (low quality evidence). None of the studies provided data
for osteoporosis.
Immediately after treatment (two to three weeks), there was evi-
dence (high risk of bias) of an improvement in nasal polyp score
for the oral steroids group compared with the control group. Re-
sults at three to six months after the end of oral steroid treatment
indicate that the magnitude of the difference between the groups
may not be sustained (high risk of bias).
No studies reported generic health-related quality of life or CT
scan score as outcomes.
Overall completeness and applicability of
evidence
All of the included studies only included adults with nasal polyps
(Alobid 2014; Benitez 2006; Ecevit 2015; Hissaria 2006; Kapucu
2012; Kirtsreesakul 2012; Vaidyanathan 2011; Van Zele 2010).
This limits the applicability of the evidence to both adults without
nasal polyps and the paediatric population with chronic rhinos-
inusitis. Two of the three ongoing studies that we identified in-
clude patients with chronic rhinosinusitis who do not have nasal
polyps (NCT00841802; NCT02367118). NCT00841802 only
includes patients with chronic rhinosinusitis without nasal polyps,
whereas the other study, NCT02367118, includes patients with
and without nasal polyps,. Evidence for oral steroids in patients
with chronic rhinosinusitis without polyps may therefore be avail-
able for the next update of this review.
The doses of oral steroids used in the trials differed. Us-
ing a steroid equivalence converter (http://www.medcalc.com/
steroid.html) for the three oral steroid drugs in the included tri-
als (prednisone, prednisolone and methylprednisolone) to con-
vert all doses into a reference drug of prednisolone, the dose of
drug ranged from 25 mg/day (Vaidyanathan 2011) to 60 mg/day
(Ecevit 2015). In the analysis, we analysed all of the doses together.
This excludes the Kapucu 2012 study, for which no outcomes are
available, which calculated the dosage based on the weight of par-
ticipants at 1 mg/kg/day methylprednisolone; for a weight of 84
kg (average weight of a UK man) this would be equivalent to 105
mg/day of prednisolone.
The primary outcomes were often either not reported or very
poorly reported within the papers. There was considerable incon-
sistency between the papers with regards to the instruments used
and how the results were reported (mean final value or change
from baseline), making the analysis of results difficult.
There was a lack of consistent information on disease-related
symptom severity. There were no studies that used a validated
tool to report this as an outcome. Of the four studies that at-
tempted to reported this outcome (Ecevit 2015; Hissaria 2006;
Kirtsreesakul 2012; Vaidyanathan 2011), only two, Ecevit 2015
and Kirtsreesakul 2012, presented data for all four of the symp-
toms required to diagnose chronic rhinosinusitis using the EPOS
2012 criteria (Appendix 3). The lack of reporting of symptoms,
particularly of facial pressure/pain and hyposmia, may have been
due to all of the study populations being composed entirely of
people with nasal polyps. The studies usually looked for changes
in symptoms associated with nasal polyps (such as nasal discharge
and obstruction) rather than more general chronic rhinosinusitis
symptoms. The facial pain/pressure symptom was not often stud-
ied.
The two studies that reported a ’symptom severity score’ with-
out providing information on the individual elements included
used scales that included items that may have been more relevant
to rhinitis outcomes (Hissaria 2006; Vaidyanathan 2011), which
limits the applicability of these results to the chronic rhinosinusi-
tis population. Vaidyanathan 2011 used ’total nasal symptoms’ to
report symptom severity, which covers five domains: two are rel-
evant to chronic rhinosinusitis symptoms (nasal congestion and
runny nose), two domains are more specific to rhinitis symptoms
(nasal itching and sneezing) and one domain relates to the impact
of the symptoms on sleeping. Similarly, Hissaria 2006 used the
nasal subscale of the RSOM-31 to look at ’symptom severity’. This
subscale measures congestion, rhinorrhoea, sneezing, hyposmia,
postnasal discharge and thick nasal debris, of which some elements
are more specific to rhinitis symptoms. These studies may change
the magnitude of the effect.
The methods used for assessing polyps were poorly reported in the
papers and the assessment of polyp bulk endoscopically was the
subject of several scoring systems (Appendix 4). Unless examina-
tions are videoed and assessed centrally, these are somewhat sub-
jective, even if previously validated, and should be seen as a guide
to responsiveness rather than an absolute measure, as these studies
did not report intra- and inter-reporter reliability. There could be
potential for bias in the way the scores have been reported, partic-
ularly in studies without blinding.
The information about adverse events was incomplete. Only three
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of eight studies included clear information about adverse events
(Hissaria 2006; Vaidyanathan 2011; Van Zele 2010). This is a
trend repeated in other conditions and reliable data for adverse
events associated with short-term steroid use have not been well
recorded in the literature (Burton 2008). Additionally, there was a
lack of long-term data from the trials, which could identify longer-
term effects of oral steroids such as osteoporosis.
There was also a lack of information on other longer-term out-
comes. Five of the eight studies only reported the results for both
arms of the trials at the end of treatment (Alobid 2014; Benitez
2006; Ecevit 2015; Hissaria 2006; Kapucu 2012). Of the three
studies that provided longer-term results, two reported outcomes
at three months (Kirtsreesakul 2012; Van Zele 2010), and one
provided six-month results (Vaidyanathan 2011).
Quality of the evidence
The quality of the evidence for all of the outcomes assessed was
low, including for the adverse events outcomes that were reported.
The quality of the evidence was affected by a number of issues:
methodological limitations, length of follow-up, validation of out-
come instruments and the size of the studies.
The studies were generally poorly reported and information about
randomisation, allocation concealment and blinding was unclear
in themajority. Five of the trials only followed up patients until the
end of oral steroid treatment (two to three weeks), which limits the
applicability of the evidence for the longer-term outcomes. Where
longer-term outcomes were presented (three to six months) it was
often found that the initial results were not sustained.
Another issue is the lack of use of validated instruments. Many
studies did not use validated patient-reported outcome measures
and some used instruments that were validated for other popula-
tions (e.g. rhinitis patients). A ’validated instrument’ is no longer
valid when used outside the population it was intended for, as the
items being used may no longer be relevant and important areas
for chronic rhinosinusitis patients may not be covered. We also
downgraded the disease severity outcome whenever an overall val-
idated disease severity score was not reported and imputations had
to be made to calculate total symptom scores (see Dealing with
missing data).
The size of the studies included in this review was generally small
with an average sample size of 60 participants (30 in each arm).
This limits how much confidence can be placed in the results.
Potential biases in the review process
What defined a ’short course’ of oral steroids was an issue that we
discussed at great length during the development of the protocol
for this review (Chong 2015). We finally agreed that up to a 21-
day course should be considered to be a short course, but there
were some opinions that the maximum duration should be 14
days. Limiting the evidence to 14 days would have excluded two
studies (Ecevit 2015; Van Zele 2010), and possibly a further study
where the duration is unclear and based on weight rather than
time (Kapucu 2012). As there were only a small number of papers
for each outcome it is not possible to evaluate the impact of this
decision.
The validation of outcome measures was a potential bias that we
identified at the protocol stage as something that could affect the
validity of the results. Many of the studies did not use patient-
reported symptom scoring scales that have been appropriately val-
idated. The lack of validated scores means that we often have to
make judgements based on the face validity of the scale, rather
than having reliable validity data. For example, in Vaidyanathan
2011, health-related quality of life was measured using a measure
that was validated in people with seasonal or perennial allergic
rhinitis but not in people with chronic rhinosinusitis, the mini-
Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). This
instrument has 14 questions covering five domains: activity limita-
tion, practical problems, nose symptoms, eye symptoms and non-
nose/eye symptoms, with a focus of eye and nose symptoms related
to allergy. Similarly, many of other studies also used instruments
that were not validated in people with chronic rhinosinusitis to
measure symptom severity.
The lack of use of validated instruments to measure patient-im-
portant outcomes, such as the impact on quality of life and disease
severity, is the probably the single most important issue that ham-
pers the ability to meta-analyse results or to compare results be-
tween studies. Validated disease-specific questionnaires exist and
future trials would benefit from including these as primary out-
come measures. Recent preliminary work in the UK has under-
lined this and identified the need to establish a core outcome set
for rhinosinusitis (Hopkins 2016).
As there was a lack of outcomes reported using validatedmeasures,
in order to enable some comparison between studies and reviews
(Chong 2016a; Chong 2016b; Chong 2016c; Head 2016a; Head
2016b), we took the decision to combine the scores for individual
symptoms to create a total symptoms score. The methods and
limitations are described in the Methods section (Dealing with
missing data). The symptoms included were based on the EPOS
2012 diagnostic criteria. However, this score was not a validated
measure and as there is no evidence on the correlation coefficient
between symptoms, the calculation could not account for it. This
may have had an effect on the magnitude of the effect size when
interpreted as a standardisedmean difference due to the potentially
higher or lower standard deviations but not in mean differences
(MD)observed.To account for the lack of validated scales used and
the lack of validated methods to sum the scores, we downgraded
all the disease severity outcomes for lack of use of validated scales
whenever this occurred.
Another potential bias in the review process was that many of
the data for the included studies were presented in the papers in
graphs or charts. Where this was the case, we contacted the study
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authors to try to obtain more precise data, however none of the
authors provided additional data. We therefore extracted the data
from the paper using an online programme (http://arohatgi.info/
WebPlotDigitizer/app/). There will inevitably be a degree of error
in using these data, both from inaccuracies during the printing
process and the process used to collect the data. We carefully con-
sidered the amount of any additional transformation of the data
where they had been interpreted from graphs (such as combining
individual symptoms into total scores) to try to minimise addi-
tional errors.
Agreements and disagreements with other
studies or reviews
The current reviewupdates a previousCochrane review (Martinez-
Devesa 2011), and it increases the scope of the review to include
patients both with and without nasal polyps.
The previous Cochrane review included three studies (Alobid
2006 - reported in this review as Benitez 2006; Hissaria 2006; Van
Zele 2010), and referenced one ongoing study. We included all
four of these studies in this updated review (including the ongoing
study, which has now been published in full - Vaidyanathan 2011).
After communication with the study author we determined that
Alobid 2006 partially reported on participants in Benitez 2006
and the author recommended that Benitez 2006 was the best paper
to use. The previous review concluded that “the limited number of
trials of moderate to poor methodological quality showed a short-
term improvement with a short (two to four-week) and variable
dose course of oral steroids in the treatment of nasal polyps.” Fur-
thermore, they highlighted the lack of long-term data preventing
any conclusions about a sustained effect of this treatment in the
management of nasal polyps. The current review presents addi-
tional evidence for the short-term effects, although the conclusion
that there is a short-term improvement after a short course of oral
steroids is still valid. In addition, this review adds three studies
that reported results at three to six months (Kirtsreesakul 2012;
Vaidyanathan 2011; Van Zele 2010). The results at three to six
months show that the magnitude of improvement is not sustained
after the oral steroid treatment period.
We changed the inclusion criteria with regards to previous surgery
from the previous review to include studies where patients had
surgery within six weeks of the start of the trial, compared with
three months for the previous review. This did not increase the
number of included studies. Some of the studies specifically inves-
tigated the use of oral steroids pre-operatively to improve surgical
field conditions during surgery (Ecevit 2015; Sieskiewicz 2006).
We included these studies if the treatment duration was equiv-
alent to the other studies included and any of the pre-specified
outcomes were measured prior to surgery (Ecevit 2015). For one
study the treatment course was only five days and the outcomes
were specifically related to surgical field conditions, and so we ex-
cluded this study (Sieskiewicz 2006).
The EPOS 2012 document splits the chronic rhinosinusitis pop-
ulation into those with and without nasal polyps. For the popula-
tion without nasal polyps we identified only one case series with
information about adverse events extrapolated from the chronic
rhinosinusitis with nasal polyps population. The recommenda-
tion, based on very weak evidence, within the EPOS document for
chronic rhinosinusitis without nasal polyps (CRSsNP) was that
“systemic corticosteroids benefit CRSsNP”. For the chronic rhi-
nosinusitis with nasal polyps (CRSwNP) population, the EPOS
document uses the three studies included in the previousCochrane
review (Alobid 2006 - reported in this study as Benitez 2006;
Hissaria 2006; Van Zele 2010) and adds an additional three stud-
ies/four papers (Benitez 2006; Vaidyanathan 2011; Martinez-An-
ton 2008 - reported in this review as Benitez 2006; Rupa 2010).
Vaidyanathan 2011 was also included in this review. After commu-
nication with the study author we confirmed that Benitez 2006,
Alobid 2006 and Martinez-Anton 2008 all contained subsets of
participants from the same trial and therefore some patients were
presented in the analysis of all three trials. The author also sug-
gested that Benitez 2006 was the best paper to use as the most
complete information for the trial and this is what is included in
this Cochrane review. We excluded Rupa 2010 from this review
as it reported on a population that was out of scope for the review
(allergic fungal rhinosinusitis). The EPOS 2012 document con-
cludes, based on strong evidence, that “Systemic corticosteroids
benefit CRSwNP but the effects are time limited post therapy”.
As part of this suite of Cochrane reviews on the interventions for
chronic rhinosinusitis, a review on the use of short-course oral
steroids as an adjunct has been published (Head 2016a). Two
studies identified in that review used oral steroids as an adjunct
treatment to either intranasal steroids (Bülbül 2013), or antibiotics
(Ozturk 2011). The trials were small, low quality and did not
report many of the pre-specified outcomes. There was not enough
evidence to support or oppose the use of oral steroids as an adjunct
to other treatments for chronic rhinosinusitis.
As the included studies did not report the incidence of adverse
events and the risk of side effects may vary according to the con-
dition that they are used to treat, it is important to consider data
from similar conditions where possible. A recent review of sys-
temic steroids in acute rhinosinusitis identified five trials includ-
ing 1193 participants, receiving either oral steroids (prednisolone
at dosages ranging from 24 mg to 80 mg for three to seven days)
or placebo, where adverse events were reported (Venekamp 2014;
Venekamp 2015). There was no difference between the active or
control arms in terms of the risk of adverse events, with respect to
mild or severe events, or the risk of discontinuation of treatment.
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
The results of this review, current to August 2015, show that there
is low quality evidence (we are uncertain about the estimates)
to suggest that, for people with chronic rhinosinusitis with nasal
polyps, adding oral corticosteroids is beneficial in reducing the
size of the polyps and probably also in reducing symptom severity
when compared to placebo. The quality of the evidence for ad-
verse effects was very low; some studies did not report these well
and there were no data on important longer-term effects. The re-
sults for longer-term outcomes, which are important to determine
whether there is sustained benefit, suggest that the difference be-
tween the groups becomes smaller, but the evidence is inconclu-
sive due its low quality. No evidence was found for people with
chronic rhinosinusitis without nasal polyps.
Short-course oral corticosteroids alone for chronic rhinosinusitis
have potential short-termbenefits with tolerated side effects.How-
ever, the beneficial effect of a short course of treatment is unlikely
to persist, hence the need for additional, ongoing topical treat-
ment. Occasional, intermittent courses of oral corticosteroids may
have a place within a long-term treatment strategy. Clear guidance
on how short courses of oral corticosteroids can be used alone or
as an adjunct to long-term topical treatment should be provided
for use in both primary and secondary care.
Implications for research
There is clearly room for more trials with adequate outcomes for
the population being addressed to further underline the role of
short-term oral steroids, including trials that assess the choice of
agent and dosing/duration. There are two scenarios where further
research would be very valuable:
• Upon entry to secondary care. When patients are initially
referred to secondary care, they are likely to have symptoms that
have not responded well to the treatment normally prescribed in
primary care (intranasal steroids and nasal irrigation). The aim of
research would be to determine whether a short course of oral
steroid treatment would allow the patient to regain control of
their symptoms and whether oral steroids may reduce the need
for surgical intervention.
• As a rescue medication, when patients who are on existing
topical treatments have an exacerbation of symptoms related to
chronic rhinosinusitis. The aim of the research would be to
determine whether a short course of oral steroids would allow the
quick relief of symptoms.
Future research should recruit patients with chronic rhinosinusitis
diagnosed using the EPOS 2012 criteria and include both patients
with and without nasal polyps (stratified randomisation by sub-
group). Oral steroids should be given for between one and three
weeks at an appropriate dose. The primary outcomes should be
relevant to patients and any disease-specific instruments should
be validated in people with chronic rhinosinusitis. Endoscopic
evaluation should not be chosen as a primary outcome because
the correlation between endoscopic results and patient symptoms
is unclear. Adverse events should be defined in the protocol and
measured during treatment and in the follow-up period.
In addition tomeasuring outcomes at the end of oral corticosteroid
treatment, future trials should follow up patients and measure
outcomes for at least six months.
This review is one of a suite of reviews of medical treatments for
chronic rhinosinusitis, each of which features its own research rec-
ommendations. Across all reviews, key features of future research
are as follows:
• Trials should be adequately powered and imbalances in
prognostic factors (for example, prior sinus surgery) must be
accounted for in the statistical analysis.
• Study participants should be diagnosed with chronic
rhinosinusitis using the EPOS 2012 criteria and should
primarily be recruited based on their symptoms. Different
patient phenotypes (that is, those with and without nasal polyps)
should be recognised and trials should use stratified
randomisation within these subgroups or focus on one or other
of the phenotypes.
• Studies should focus on outcomes that are important to
patients and use validated instruments to measure these.
Validated chronic rhinosinusitis-specific health-related quality of
life questionnaires exist, for example the Sino-Nasal Outcome
Test-22 (SNOT-22). Patients may find dichotomised outcomes
easiest to interpret; for example the percentage of patients
achieving a minimal clinically important difference (MCID) or
improvement for that outcome. Such MCIDs or cut-off points
should be included in the study protocol and clearly outlined in
the methods section.
• Trials and other high-quality studies should use consistent
outcomes and adhere to reporting guidelines, such as
CONSORT, so that results can be compared across future trials.
The development of a standardised set of outcomes, or core
outcome set, for chronic rhinosinusitis, agreed by researchers,
clinicians and patients, will facilitate this process.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alobid 2014
Methods 2-arm, non-blinded, parallel-group RCT, with a 2-week duration of treatment and fol-
low-up
Participants Location: Spain, 1 site
Setting of recruitment and treatment: rhinology and smell clinic, department of otorhi-
nolaryngology, hospital clinic, Barcelona
Sample size:
Number randomised: 92 (it is unclear if these were all randomised or if the 3 drop-outs
occurred prior to randomisation)
Number completed: 67 in intervention group, 22 in comparison group
Participant (baseline) characteristics:
• Age: 51 ± 12 (22 to 84)
• Gender (%M/%F): 65/35
• Main diagnosis: moderate to severe nasal polyps
• Polyps status: 100% with polyps
• Mean polyps score at baseline: no information
• Previous sinus surgery status: 6 (6.7%)
• Previous courses of steroids: no information
Other important effect modifiers:
• Asthma: oral steroids: 41 (61%); no treatment: 14 (64%)
• Aspirin-intolerant asthma: Group A: 25 (37%); Group B: 5 (23%)
Inclusion criteria: diagnosis of bilateral nasal polyps was based on the EPOS criteria:
“Presence of two or more nasal symptoms, one of which should be either nasal blockage
or nasal discharge, and/or the reduction/loss of sense of smell, and/or facial pain for more
than12weeks, and/or the presence of nasal polyps by nasal endoscopy ormucosal changes
within the ostiomeatal complex, and/or paranasal sinuses by computed tomography
(CT) scan”
Exclusion criteria: none listed
Interventions Intervention (n = 67): oral prednisone (30 mg daily for 4 days followed by a 2-day
reduction of 5 mg) and intranasal budesonide 800 µg daily (400 µg twice daily) for 2
weeks
Comparator group (n = 22): no corticosteroid treatment for 2 weeks
Use of additional interventions (common to both treatment arm): both groups had
a 4-week washout period for intranasal and oral steroids. No other adjunct treatment is
listed
Outcomes Outcomes of interest in the review:
Primary outcomes
1. None presented
Secondary outcomes
1. Polyp grade measured by CT scan of paranasal sinuses, staged using the Lund-
Mackay score (0 - no opacity; 1 - partial opacity; 2 - total opacity for each of the
sinuses. The ostiomeatal complex was also bilaterally scored 0 for no obstruction or 2
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when obstructed) at 2 weeks.
Other outcomes reported by the study:
• Nasal congestion measured on a 4-point Likert scale (0 to 3) at 2 weeks
• Loss of sense of smell, measured by Barcelona Smell Test 24 (BAST-24) at 2 weeks
• Polyp tissue eosinophilia (from biopsies at baseline and after oral steroid
treatment)
• Nasal nitric oxide
Funding sources “This article was partially sponsored by a research project from Fondo de Investigacion
Sanitaria (FIS 99-0133), Instituto de Salud Carlos III.” There was no information re-
garding the funding of the original study
Declarations of interest No information is provided in the paper
Notes In the group receiving oral steroids, the treatment period was followed up by a 10-week
course of INCS. The “no steroids treatment” group were not followed up after 2 weeks
and so these results have not been presented
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “…randomised…”
Comment: no information about the ran-
domisation procedures for the trial
Allocation concealment (selection bias) Unclear risk Comment: there is no information about
the allocation concealment. Given the trial
was not blinded, there is reason to believe
that the study personnelmay have been able
to influence the groups into which partici-
pants were allocated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: the trial does not appear to be
blinded to patients or study personnel. The
comparison grouphadno steroid treatment
and did not receive placebo
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: the main outcomes were sub-
jective outcomes rated by patients. There
was no mention of blinding of outcome as-
sessors (for endoscopy) included in the pa-
per. Since the control arm received no treat-
ment, the risk of bias is high
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: paper indicates that 92 patients
were recruited but only 89 patients are ac-
counted for in the analysis. The 3 drop-
outs are identified but there is no indication
38Short-course oral steroids alone for chronic rhinosinusitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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if they dropped out prior to randomisation
or after randomisation. The impact of the
3 drop-outs (3%) is likely to be small
Selective reporting (reporting bias) Unclear risk Comment: adverse event data are not pre-
sented in the paper. No protocol for the
trial could be found
Other bias Unclear risk Comment: only details of the validation of
the smell test used in the study (BAST-24)
were provided. No details of validation for
other outcomes (e.g. 0- to 3-point Likert
scale used to assess nasal congestion)
Benitez 2006
Methods 2-arm, non-blinded, parallel-group RCT, with 2-week duration of treatment and follow-
up
Participants Location: Spain, 1 site
Setting of recruitment and treatment: rhinology unit, ENTdepartment, hospital clinic,
Barcelona
Sample size: 84
Number randomised: 63 in intervention group, 21 in comparison group
Number completed: 63 in intervention group, 21 in comparison group
Participant (baseline) characteristics:
• Age: oral steroids: 51 ± 2.8; no treatment: 53 ± 3.8
• Gender: M/F: 55/29
• Main diagnosis: severe nasal polyps
• Polyps status: 100% with polyps
• Previous sinus surgery status: no information
• Previous courses of steroids: information not provided
Other important effect modifiers:
• Aspirin sensitivity: 23 (27.4%) (not given per group)
• Comorbidities of asthma: 40 (47.6%) (not given per group)
Inclusion criteria: diagnosis of severe nasal polyps based on nasal endoscopic examina-
tion (mean score of 2.7 over 3 using the Lildholdt score)
Nasal polyps score: 0 - no polyps; 1 - mild polyposis; 2 - moderate polyposis; 3 - severe
polyposis
Exclusion criteria: patients with a steroid contraindication
Interventions Intervention (n = 63): oral prednisone, 30 mg daily for 4 days followed by 2-day
reduction of 5 mg, total duration 14 days
Comparator group (n = 21): no steroid treatment
Use of additional interventions (common to both treatment arms): asthmatic patients
did not modify their treatment during the study. No patients were receiving treatment
with leukotriene antagonists
(Note: both groups had a 4-week washout period for intranasal and oral steroids)
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Outcomes Outcomes of interest in the review:
Primary outcomes:
1. Disease severity symptom score; measured individual symptoms of nasal
obstruction, loss of sense of smell, rhinorrhoea and sneezing, on a 4-point scale (0 to 3)
at baseline and 2 weeks
Secondary outcomes
1. Endoscopy (polyp size); using the Lildholdt scale (see inclusion criteria) at
baseline and 2 weeks
Other outcomes reported by the study:·
• Allergy study
• Nasal patency
Funding sources “Generalitat deCatalunya (2001SGR00384), Red RESPIRA (FIS, V-2003-REDC11D-
0) and Fondo de Investigaciones Sanitarias (99-3121m PI020329)”
Declarations of interest No information provided
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: study design details that the
study was “randomised” but no further de-
tails were provided
Allocation concealment (selection bias) Unclear risk Comment: no details about allocation con-
cealment were provided in the paper
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: the control group received no
steroid treatment or placebo. No mention
of blinding of participants or personnel was
included in the paper
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: the main outcomes were sub-
jective outcomes rated by patients. There
was no mention of blinding of outcome as-
sessors (for endoscopy) included in the pa-
per. Since the control arm received no treat-
ment, the risk of bias is high
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: there was no mention of any-
one who dropped out of the trial or had to
discontinue for any reason. However, they
also did not state how many patients were
analysed for each outcome
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Selective reporting (reporting bias) Unclear risk Comment: adverse event data are not pre-
sented in the paper. No protocol for the
trial could be found
Other bias Unclear risk Comment: no information is provided
about the validation of the symptom scores
used
Ecevit 2015
Methods 2-arm, double-blind, parallel-group RCT, with a 17-day duration of oral steroid treat-
ment
Participants Location: Turkey, 1 site
Setting of recruitment and treatment: Department of Otorhinolaryngology - Head
and Neck Surgery, Dokuz Eylul University Hospital
Sample size: 23
Number randomised: 11 in intervention group, 12 in comparison group
Number completed: 10 in intervention group, 12 in comparison group
Participant (baseline) characteristics:
• Mean age ± SD: oral steroids: 45.6 ± 11.5; placebo: 26.6 ± 43.3
• Gender (M/F): oral steroids: 9/1; placebo: 8/4
• Main diagnosis: patients with nasal polyps who did not respond to a 6-week
course of fluticasone nasal drops (see notes below)
• Polyps status: 100% with polyps
• Preoperative endoscopic polyp score: score 2/3: oral steroids: 4/6; placebo: 4/8
• Previous sinus surgery status: no information provided
• Previous courses of steroids: no information provided
• Other important effect modifiers: no information provided
Inclusion criteria: nasal polyps, age between 18 and 65 years, endoscopic stage II or III
nasal polyposis patients
Nasal polyps score: graded according to the following criteria: 0: nopolyp; 1:mild polyposis
(small polyps not reaching the upper edge of the inferior turbinate); 2:moderate polyposis
(medium polyps between the upper and lower edges of the inferior turbinate); 3: severe
polyposis (large polyps reaching the lower edge of the inferior turbinate, polyps from
posterior ethmoidal sinuses, or both)
Exclusion criteria: hypertension, type I or II diabetes mellitus, the signs of systemic
infection, pregnancy or lactation, any type of M. tuberculosis infection, peptic ulcer,
viral infection (measles, chicken pox or ocular herpes), myasthenia gravis, stage I nasal
polyposis, aspirin intolerance, previous major head trauma
Interventions Intervention (n = 11): prednisolone, oral, 60 mg/day (6 tablets per day) for 7 days, then
reduced to 10 mg (1 tablet) taken every other day, stopping on day 17
Comparator group (n = 12): placebo, 6 tablets per day for 7 days, then reduced to 1
tablet every other day, stopping on day 17
Use of additional interventions (common to both treatment arms): none listed
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Outcomes Outcomes of interest in the review:
Primary outcomes
1. Disease severity, measured by visual analogue scale of 0 to 10 (0 no complaint to
10 most annoying) for a combination of factors relating to sense of smell, nasal
discharge, nasal obstruction and pressure over the sinuses
Other outcomes reported by the study:
• Sense of smell with Connecticut Chemosensory Clinical Research Centre
(CCCRC) butanol olfactory threshold test
• Peak nasal inspiratory peak flow (PNIF)
• Video scoring for grading the surgical field based on the Boezaart et al grading
system for assessment of bleeding during endoscopic sinus surgery
Funding sources “The authors have no funding, financial relationships, or conflicts of interest to disclose”
Declarations of interest “The authors have no funding, financial relationships, or conflicts of interest to disclose”
Notes The patients who met the inclusion criteria gave informed consent and were prescribed
fluticasone nasal drops 1 x/day, 200 mg, for 6 weeks. Patients who did not respond to
this medical treatment were evaluated for the study
All patients in the trial underwent surgery between the 15th and 17th day. Outcomes
presented for this review are the pre-operative results
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Every eight boxes, including four
study drug boxes and four placebo drug
boxes, respectively, were assembled as a
group by the pharmacy department.”
Comment: randomisation in blocks of 8
(pg 2042, col 1, para 6)
Allocation concealment (selection bias) Low risk Quote: “…The hospital pharmacy depart-
ment performed the drug/placebo random-
ization, and the identity of the contents in
the boxes was not disclosed to any clini-
cians interacting with patients throughout
the study”
Comment: pg 2042, col 1, para 6
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “…the identity of the contents in
the boxes was not disclosed to any clini-
cians interacting with patients throughout
the study”
“The surgeon was blinded to the patient
treatment group”
Comment: pg 2042, col 1, para 6/7. It is
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unclear whether the placebo tablets provide
adequate masking in terms of taste, since
prednisolone is bitter and may be recognis-
able to patients
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: from the flowchart on pg 2042
it appears that the codes were broken after
all of the data had been collected
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: only 1 patient did not complete
the study (4.3%). The drop-out reason was
that the patient was not given the study
medication after surgery. No intention-to-
treat analysis was completed
Selective reporting (reporting bias) Low risk Comment: outcomes appear to be reported
well in the paper. No protocol for the trial
could be found
Other bias Unclear risk No information about the validation of any
outcomes
The mean age of participants in the oral
steroid groupwas 45.6 ± 11.5 and themean
age in the control group was reported as
26.6 ± 43.6. This may be a reporting error
since the range in the control group is 26
to 58 years
Hissaria 2006
Methods 2-arm, double-blinded, parallel-group RCT, with 14 days duration of treatment follow-
up
Participants Location: Australia, unclear number of sites
Setting of recruitment and treatment: allergy outpatient clinics
Sample size:
Number randomised: 20 in intervention group, 21 in comparison group
Number completed: 20 in intervention group, 20 in comparison group
Participant (baseline) characteristics:
• Age: oral steroids: 49 ± 13; placebo: 48 ± 12
• Gender (M/F): oral steroids: 7/13; placebo: 12/8
• Main diagnosis: symptomatic polyp disease
• Polyps status: 100% with polyps
• Previous sinus surgery status: oral steroids: 17 in 8 participants; placebo: 23 in 13
participants
• Previous courses of steroids: oral steroids: 11; placebo: 12
Other important effect modifiers:
• History of aspirin sensitivity: oral steroids: 2; placebo: 12
43Short-course oral steroids alone for chronic rhinosinusitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hissaria 2006 (Continued)
• History of atopy: oral steroids: 18; placebo: 20
• Use of intranasal corticosteroids: oral steroids: 11; placebo: 11
• Use of antihistamines: oral steroids: 7; placebo: 6
• Use of nasal decongestants: oral steroids: 5; placebo: 4
Inclusion criteria: aged 18 to 65 years drawn mainly from allergy outpatient clinics who
had symptomatic polyp disease diagnosed on nasoendoscopy
Exclusion criteria: previous use of oral steroids, unstable asthma, recent sinus surgery,
acute infection within 1 month of recruitment, polyps caused by cystic fibrosis or mu-
cociliary disorders, diabetes mellitus, cataract, glaucoma, fungal sinusitis, contraindica-
tions for MRI scanning, or any other significant comorbid condition that contraindi-
cated the use of systemic corticosteroids
Interventions Intervention (n = 20): prednisolone, 50 mg/day for 14 days
Comparator group (n = 21): placebo, for 14 days
Use of additional interventions (common to both treatment arms): participants were
allowed to continue the use of regular antihistamines (13/40), topical corticosteroids
(22/40), or both
Outcomes Outcomes of interest in the review:
Primary outcomes
1. Health-related quality of life, measured by Rhinosinusitis Outcome Measures-31
(RSOM-31) at 2 weeks (Note: the questionnaire was modified to exclude the
“importance” parameter)
2. Health-related quality of life, measured by physician assessment of nasal
symptoms (6 scales: congestion, hyposmia, rhinorrhoea, sneezing, postnasal drip and
itch) and other related symptoms (4 scales each for eyes and ears and 2 scales for
general well-being) on a visual analogue scale of 1 to 5 (mild to severe) based on the
patient history; at 2 weeks
3. Disease severity, measured by physician assessment of nasal symptoms (6 scales:
congestion, hyposmia, rhinorrhoea, sneezing, postnasal drip and itch) on a visual
analogue scale of 1 to 5 (mild to severe) based on the patient history; at 2 weeks
4. Significant adverse effect: mood or behavioural disturbances
Secondary outcomes:
1. Polyps size measured by endoscopic appearance. Observers selected the group of
images showing the more extensive/larger polyps and estimated the percentage
reduction in polyp size in the other group. The results from the assessment of 4
clinicians (3 immunologists and 1 ear, nose and throat surgeon) were pooled for
analysis.
2. Other adverse effects: gastrointestinal disturbances
3. Other adverse effects: insomnia
Other outcomes reported by the study:
• MRI of the paranasal sinuses before and after treatment
Funding sources No information provided
Declarations of interest “P. Wormwald receives royalties from Medtronic Xomed for instruments designed. The
rest of the authors have declared that they have no conflict of interest.”
Notes -
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “… randomized by the hospital
pharmacy to receive the study medication
...”
Comment: pg 129, col 1, para 2
No information on sequence generation
Allocation concealment (selection bias) Unclear risk Comment: no information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “These patients… were blinded to
their treatment status”; “study personnel
were not informed of the patient’s treat-
ment status until all assessments were com-
pleted”
Comment: pg 129, col 1, para 2. It is un-
clear whether the placebo tablets provide
adequate masking in terms of taste, since
prednisolone is bitter and may be recognis-
able to patients
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “study personnel were not in-
formed of the patient’s treatment status un-
til all assessments were completed”
Comment: pg 129, col 1, para 2
Blinding of nasoendoscopy scans (pg 129,
col 2, para 3) were well documented when
describing the outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 1 patient did not complete the
study and their data were not included in
the analysis
Selective reporting (reporting bias) High risk Comment: nasoendoscopy findings were
reported inconsistently within the paper
using differing criteria which had not been
pre-specified in themethods section. There
was concern that the cut-off points for re-
porting could have been chosen after the
results were available
In addition, some of the scales used are
unclear. No information is provided for
the modified RSOM-31 instrument or the
RSOM-31 nasal subscale
No protocol for the trial could be found
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Other bias High risk The RSOM-31 was modified, without fur-
ther evidence of validation, and it is unclear
whether themethods for measuring change
in polyps size were validated
Kapucu 2012
Methods 4-arm, unblinded, parallel-group RCT, with unclear duration of treatment and 7-day
duration of follow-up
Participants Location: Turkey, unclear number of sites (probably 1)
Setting of recruitment and treatment: Department of Otorhinolaryngology, GATA
medical faculty, Ankara
Sample size:
• Number randomised: 12 in intervention group, 12 in comparison group
• Number completed: 12 in intervention group, 12 in comparison group
Participant (baseline) characteristics: (based on all 4 groups)
• Mean age (range): 32.2 years (20 to 60 years)
• Gender M/F: 40/8
• Main diagnosis: nasal polyposis
• Polyps status: 100% with polyps
• Previous sinus surgery status: 0% had previous polyp surgery
• Previous courses of steroids: information not provided
• Other important effect modifiers: none listed
Inclusion criteria:
Nasal polyps diagnosed by computed tomography
Exclusion criteria: past surgeries for nasal polyps, any glucocorticoid usage for any
reason within 1 month, nasal polyp that was not eosinophilic nasal polyp according
to the pathology study, fungal chronic sinusitis, age younger than 15 years, Churg-
Strauss syndrome, immunodeficiency, Kartagener’s syndrome, Young’s syndrome, cystic
fibrosis, antrochoanal polyp and unilateral nasal polyp. Additional exclusion criteria
were any contraindications for steroid treatment (such as glaucoma, peptic ulcer, acute
psychosis, herpetic keratitis, chronic infections, severe osteoporosis, severe hypertension,
uncontrolled diabetes mellitus, thromboembolic predisposition, newly formed bowel
anastomosis, diverticulitis and Cushing’s syndrome)
Interventions Intervention (n = 12): oral methylprednisolone (Prednol 16 mg tablet, Prednol 4 mg
tablet; Mustafa Nevzat Pharmaceutical, Istanbul, Turkey), 1 mg/kg/day. The dose was
applied for 3 days and tapered gradually, with a reduction rate of 8 mg/3 days. The
duration of drug use varied for each patient changing according to his or her weight
Comparator group (n = 12): no medication was given
Use of additional interventions (common to both treatment arm): no information
Outcomes No primary, secondary or adverse events were reported
Other outcomes reported by the study:
• Apoptotic Index. Samples collected on day 7 (Intervention group) and visit 1
(control group)
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Funding sources “None”
Declarations of interest Competing interests “None”; sponsorships “None”
Notes 2 of the 4 groups within the study were not recorded in this data extraction. The inter-
ventions in the 2 additional groups were: intra-polyp injection and INCS alone (for 30
days)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “…randomly assigned… ”
Comment: pg 564, col 1, para 3
Allocation concealment (selection bias) Unclear risk Comment: no information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: no medication was given to the
comparator group, implying there was no
placebo used. It is assumed that the study
is not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: no information, but the study
only measures objective outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no information. The paper im-
plies that all patients completed treatment
and were recorded in the outcomes
Selective reporting (reporting bias) Unclear risk Comment: no outcomes directly relevant
to patients were reported. No protocol for
the trial could be found
Other bias Unclear risk Comment: no information about the vali-
dation of outcomes
Kirtsreesakul 2012
Methods 2-arm, double-blind, parallel-group RCT, with 14 days oral steroid treatment duration
and 12-week follow-up period
Participants Location: 1 site, Thailand
Setting of recruitment and treatment: Allergy and Rhinology Clinic, Prince of Songkla
University
Sample size: 117
Number randomised: 69 in intervention group, 48 in comparison group
Number completed: 67 in intervention group, 47 in comparison group
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Participant (baseline) characteristics:
• Age: oral steroids: 45.3; placebo: 46.4
• Gender (M/F): oral steroids: 43/24; placebo: 29/18
• Main diagnosis: bilateral nasal polyps
• Polyps status: 100% with polyps
• Previous sinus surgery status: no information provided
• Previous courses of steroids: no information provided
• Concurrent disease:
◦ Aspirin sensitivity: oral steroids: 4; placebo: 4
◦ Asthma: oral steroids: 17; placebo: 14
◦ Positive allergy skin test: oral steroids: 37; placebo: 25
◦ Positive meatal discharge: oral steroids: 29; placebo: 18
◦ Positive sinus radiography: oral steroids: 52; placebo: 40
◦ Baseline total nasal polyps score: oral steroids: 3.37 +/- 1.37; placebo: 3.13
+/- 1.09
Inclusion criteria: patients with benign bilateral nasal polyps diagnosed clinically and
confirmed by nasal endoscopy
Nasal polyps score: graded on a4-point scale (0 to 3): 0 - no polyps, 1 -mild polyposis (small
polyps, extending downward from the upper nasal cavity but not below the upper edge of
the inferior turbinate, causing only slight obstruction), 2 - moderate polyposis (medium-
sized polyps, extending downward from the upper nasal cavity and reaching between the
upper and lower edges of the inferior turbinate, causing troublesome obstruction), 3 -
severe polyposis (large-sized polyps, extending downward from the upper nasal cavity
and reaching below the lower edge of the inferior turbinate, causing total or almost total
obstruction). The total nasal polyps score was calculated as the sum of the polyps scores
for each nostril
Exclusion criteria: patients with symptoms or physical signs suggestive of renal disease,
hepatic disease, diabetes mellitus, cataract, glaucoma, cardiovascular disease, unstable
asthma, cystic fibrosis, mucociliary disorders, immunocompromise, severe septal devi-
ation or acute infection within the previous 2 months. Patients who had used nasal,
inhaled or systemic steroids within 2 months; an antihistamine within 2 to 7 days; and/
or a decongestant within 2 days or had had previous sinonasal surgery were also excluded
Interventions Intervention (n = 67): oral prednisolone 50 mg daily for 14 days
Comparator group (n = 47): placebo tablet daily for 14 days
Use of additional interventions (common to both treatment arms): at the end of the
“test treatment” stage all patients were then treated with administration of mometasone
furoate nasal spray (MFNS) at 200 µg twice daily for 10 weeks
Medications for rhinitis or allergy or nasal saline irrigation were not allowed during their
participation in the study
Outcomes Primary outcomes
1. Disease severity at 2, 7 and 12 weeks, measured the following symptoms; blocked
nose, runny nose, sneezing, nasal itching, hyposmia, postnasal drip, cough and
sinonasal pain. Each symptom was measured on a 7-point Likert scale.
Secondary outcomes
1. Nasal polyp size measured by endoscopic appearance. Scored on a scale of 0 to 3
(see inclusion criteria for details) for each nostril and then combined for a total nasal
polyp score.
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2. Other adverse effects: gastrointestinal disturbances
3. Other adverse effects: insomnia
Other outcomes reported by the study:
• Nasal patency (tested with nasal and oral peak expiratory flow index)
Funding sources “Funded by the Faculty of Medicine, Prince of Songkla University”
Declarations of interest “The authors have no conflicts of interest to declare pertaining to this article”
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly assigned
at a 3:2 ratio”
Comment: pg 456, col 1, last para. There
is no information regarding the method of
sequence generation
Allocation concealment (selection bias) Unclear risk Quote: “The study personnel were not in-
formed of the treatmentmodality of the pa-
tients until all assessments were completed”
Comment: no details on how the patients
were allocated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “... prednisolone or placebo”, “…
were blinded to their treatment regimen.”
(pg 455, col 2, last para)
“The study personnel were not informed
of the treatment modality of the patients
until all assessments were completed” (pg
456, col 2, para 1)
Comment: it is unclear whether the
placebo tablets provide adequate masking
in terms of taste, since prednisolone is bit-
ter and may be recognisable to patients
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The study personnel were not in-
formed of the treatmentmodality of the pa-
tients until all assessments were completed”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: low numbers of patients
dropped out - unlikely to affect the overall
result
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Selective reporting (reporting bias) Low risk Comment: appears that all of the outcomes
listed were adequately reported in the pa-
per.Noprotocol for the trial could be found
Other bias Unclear risk Comment: no information about the vali-
dation of the “total nasal symptom score”
Vaidyanathan 2011
Methods 2-arm, double-blind, parallel-groupRCT,with 2-week durationof oral steroid treatment,
followed by a 6-month duration of intranasal steroid treatment and duration of follow-
up
Participants Location: Scotland, 1 site
Setting of recruitment and treatment: speciality referral clinic
Sample size:
Number randomised: 30 in intervention group, 30 in comparison group
Number completed: 27 in intervention group, 24 in comparison group
Participant (baseline) characteristics:
• Mean age (range): oral steroids: 49 (24 to 70); placebo: 52 (17 to 78)
• Gender male/female: oral steroids: 14/16; placebo: 20/10
• Main diagnosis: non-smoking adults who had CRS with nasal polyposis, with or
without asthma
• Polyps status: 100% with polyps
• Mean baseline polyps grade (scale of 0 to 6): oral steroids: 4.7; placebo: 4.8
• Previous sinus surgery status: oral steroids: 7 (23%); placebo: 9 (30%)
• Previous courses of steroids: oral steroids: 3 (10%); placebo: 4 (13%)
Other important effect modifiers
• History of aspirin intolerance: oral steroids: 7 (23%); placebo: 9 (30%)
• Atopy: oral steroids: 13 (43%); placebo: 16 (53%)
• Asthma: oral steroids: 11 (37%); placebo: 16 (53%)
Inclusion criteria: diagnosis of CRS with nasal polyposis made on the basis of the EPOS
2007 criteria
Inclusion criteria were the presence on nasoendoscopy of bilateral moderate-sized to
large nasal polyps (grade > 1) according to the Lildholdt scale and at least 2 of anterior
or posterior nasal discharge, nasal obstruction or decreased sense of smell for more than
12 weeks
Lildholdt nasal polyps scale: 0, no nasal polyps; 1, small polyps confined to the middle
meatus; 2, moderate sized polyps not crossing the lower edge of the inferior turbinate;
3, large polyps crossing the lower edge of the inferior turbinate
Exclusion criteria: exclusion criteria included treatment with an oral corticosteroid in
the past 3 months, sinus surgery in the past year, recent upper respiratory tract infection,
mechanical nasal airway obstruction of more than 50% due to septal deviation, or
pregnancy or lactation
Interventions Intervention (n = 30): prednisolone tablets, 25 mg/day, 2 weeks
Comparator group (n = 30): placebo tablets, daily, 2 weeks
Use of additional interventions (common to both treatment arm):
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All patients underwent a 2-week ’run-in’ period prior to the trial during which therapy
for CRS with nasal polyps was stopped
After the 2-week oral steroid treatment period both study arms received fluticasone
propionate nasal drops, 400 µg twice daily, for 8 weeks then fluticasone propionate nasal
spray, 200 µg twice daily for a further 18 weeks
No other rhinitis medications were permitted, including antihistamines, leukotriene
receptor antagonists, intranasal corticosteroids or nasal decongestants. No antibiotics
were permitted during the study
Outcomes Primary outcomes
1. Health-related quality of life, measured by Juniper mini Rhinoconjunctivitis
Quality of Life Questionnaire (RQLQ) at time point 2 weeks and 6 months
2. Disease severity, measured by total nasal symptoms score (no further details) at 2
weeks and 6 months. (In addition, sense of smell was assessed at 2 weeks and 6 months
in 2 ways: 10 cm visual analogue scale and Pocket Smell Test).
Secondary outcomes
1. Endoscopic score (nasal polyp score) measured at 2 weeks and 6 months
Other outcomes reported by the study:
• Peak nasal inspiratory flow rate
• Serum eosinophil-derived neurotoxin
• High-sensitivity C-reactive protein levels
• Overnight urinary free cortisol
• Overnight urinary cortisol corrected for creatinine
• 08:00 am serum cortisol
• Low-dose 1 µg adrenocorticotropic hormone-simulation test
• Markers of bone turnover
Funding sources “Chief Scientist Office, Scotland; National Health Service Tayside Small Grants Scheme;
and an Anonymous Trust grant from University of Dundee.”
Declarations of interest The link from the paper to the website does not appear to list any declarations of interests
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “An independent, off-site clini-
cal trials pharmacist (Pharmacy Production
Unit, Western Infirmary, Glasgow, United
Kingdom) used a computer-generated ran-
dom allocation sequence to randomize the
trial, using block randomization with a
block size of 4.”
Comment: pg 294, col 2, para 5
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Allocation concealment (selection bias) Low risk Quote: “Tablets were distributed in sealed
opaque envelopes at the research unit, in
sequential order, by a laboratory techni-
cian who was not directly involved with the
study.”
Comment: pg 294, col 2, para 5
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “The same pharmacist masked and
blinded the 25-mg prednisolone tablet and
an identical placebo tablet to double-blind
the study from the investigator and partic-
ipants.” (pg 294, col 2, para 5)
“Three patients in the prednisolone group
and 4 in the placebo group had previously
received oral steroids” (pg 297, col 2)
Comment: it is unclear whether the
placebo tablets provide adequate masking
in terms of taste, since prednisolone is bit-
ter and may be recognisable to patients
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Standard video sequences were
stored on a computer and viewed by 2 in-
dependent observers, who were blinded to
patient, treatment, and sequence.Disagree-
ments were resolved by discussion.”
Comment: pg 295, col 2, para 1
Patients and the main outcome asses-
sors should remain adequately blinded
throughout. The other outcomes were as-
sessed by 2 blinded outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “… We included all patients who
received the allocated intervention in the
analysis”
Comment: pg 295, col 2, para 3
5 patients discontinued after the 2-week
treatment with oral corticosteroids; 4 of
these were in the oral steroids group. An-
other 2 dropped out from each group by
the 3-month follow-up (total 9/60, 15%
overall; 10% in treatment group, 20% in
control group)
The results table gives different numbers
of participants included in each analysis,
which are closer to the number of patients
available, rather than patients randomised.
It is unclear why there is a discrepancy
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Selective reporting (reporting bias) Unclear risk Comment: all outcomes were reported in
the results as described in the methods sec-
tion. The methods for collecting data for
adverse events (other than biological assays)
were not reported. The paper reports that
no oral steroid-specific adverse events were
reported, but it is unclear whether the pa-
tients were specifically asked
The protocol document was available
(NCT00788749) and the outcomes appear
to be consistent between the protocol and
the paper
Other bias Unclear risk Comment: there is no information about
the total symptom score (e.g. validation)
Study used the RQLQ (Rhinoconjunctivi-
tis Quality of Life Questionnaire), which is
validated for patients with allergy. Many of
the items are not relevant for CRS patients,
while items related to smell and sinonasal
pain were not included
Van Zele 2010
Methods 3-arm, double-blind, multicentre, parallel-group RCT, with 20 days duration of treat-
ment and 12 weeks duration of follow-up
Participants Location: 5 sites in Belgium, Germany, Holland and Australia
Setting of recruitment and treatment: not given
Sample size: 47
Number randomised: 14 in oral steroids, 19 in placebo
Number completed: 14 in oral steroids, 12 in placebo
Participant (baseline) characteristics:
• Mean age (SEM): oral steroids: 48.89 (3.23); placebo: 54.67 (3.07)
• Gender (M/F): oral steroids: 12/2; placebo: 15/4
• Main diagnosis: recurrent bilateral nasal polyps after surgery or massive bilateral
nasal polyps (grade 3 or 4)
• Polyps status: 100% with polyps
• Mean total polyp score (SEM): oral steroids: 5.86 (0.27); placebo: 6.16 (0.29)
• Previous sinus surgery status: 100% with previous surgery
• Previous courses of steroids: no information
Other important effect modifiers:
• Allergy (%): oral steroids: 5 (35.7); placebo: 11 (57.9)
• Asthma (%): oral steroids: 6 (42.9); placebo: 5 (26.3)
• Aspirin intolerance (%): oral steroids: 2 (14.3); placebo: 5 (26.3)
Inclusion criteria:
Participants had to be at least 18 years with a diagnosis of bilateral nasal polyps at
screening and baseline that have recurred after surgical resection or nasal polyps that are
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grades 3 or 4 in both nares using the polyp scoring system
Women of childbearing potential had to use a medically acceptable form of birth control
as defined by the study. Male participants had to agree to use an adequate form of birth
control for the duration of the study as defined by the study
Participants with concurrent asthma had to be maintained on no more than 1000 µg/
day beclomethasone dipropionate or the equivalent
Nasal polyp score: 0 - no polyp; 1 - small polyps in the middle meatus not reaching
below the inferior border of the middle concha; 2 - polyps reaching below the lower
border of the middle turbinate; 3 - large polyps reaching the lower border of the inferior
turbinate or polypsmedial to themiddle concha, 4 - large polyps causing almost complete
congestion/obstruction of the inferior meatus
Exclusion criteria: the following are exclusion criteria for the study: pregnancy, breast-
feeding or premenarcheal;
oral corticosteroids within the 3 months before screening; systemic fungoid infections;
known allergic reaction on methylprednisolone or tetracyclines; hypertension; diabetes
(type 1 and 2); glaucoma; tuberculosis; herpes infection; zona ophthalmica; antineu-
trophil cytoplasmic antibodies such as Wegener granulomatosis, Churg-Strauss syn-
drome and microscopic polyangiitis
Participants with acute sinusitis or concurrent nasal infection or participants who have
had a nasal or upper respiratory tract infection within 2weeks of the screening visit; cystic
fibrosis, primary ciliary dysfunction or Kartagener syndrome by history; those diagnosed
with a parasitic infection; HIV-positive or positive to hepatitis B surface antigen or C
antibodies
Participants must not have had an acute asthmatic attack requiring admission to a hos-
pital (excluding emergency department visits that resulted in direct discharge without
hospitalisation) within the 4 weeks before screening
Participants must not have received immunotherapy within the previous 3 months
Interventions Intervention (n = 14): oral methylprednisolone (32 mg/day on days 1 to 5; 16 mg/day
on days 6 to 10; 8 mg/day on days 11 to 20)
Control (n = 19): placebo, unlabelled lactose capsules, 20 days
Use of additional interventions (common to all treatment arm):
Systemic or local corticosteroids or antibiotics were not allowed; if necessary nasal cor-
ticosteroids were permitted as rescue medication 2 months after dosing with the study
medication
Outcomes Primary outcomes:
1. Disease severity, measured by patient-assessed symptoms (anterior rhinorrhoea,
nasal obstruction, post-nasal drip and loss of sense of smell) at 20 days and 12 weeks.
Details on the scales used to record symptoms are not provided within the paper.
2. Significant adverse effect: mood or behavioural disturbances
Secondary outcomes:
1. Polyps size measured by endoscopic appearance using scale as presented in the
inclusion criteria
2. Other adverse effects: gastrointestinal disturbances
3. Other adverse effects: insomnia
Other outcomes reported by the study:
• Nasal peak inspiratory flow
• Blood analysis for eosinophils, eosinophilic cationic protein and soluble IL-5
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receptor α
• Nasal secretion analysis for eosinophilic cationic protein, IL-5, IgE, matrix
metalloprotease-9, myeloperoxidase
• Need for rescue surgery and need for rescue nasal steroids
Funding sources “Supported by a grant from the Flemish Scientific Research Board, FWO Nr. A12/5-
HBKH3 (holder of a Fundamenteel KlinischMandaat), by a postdoctoral grant from the
Research Foundation Flanders (FWO), and by postdoctoral mandate from the Research
Foundation Flanders (FWO).”
Declarations of interest “Disclosure of potential conflict of interest: P. J. Wormald has received royalties from
Medtronic ENT, is a consultant for NeilMed, and has received research support from
the Garnett Passe and Rodney Williams Foundation. W. Fokkens has received research
support from GlaxoSmithKline and Stallergenes. A. Beule has received research support
from the European Union. The rest of the authors have declared that they have no
conflict of interest.”
Notes 3rd arm of the study was antibiotics (doxycycline). Results for this arm of the study are
included in Head 2016b.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Eligible patients were randomly
assigned to 3 groups by individuals not in-
volved in the study.”
Comment: pg 1070, col 1, para 3. No in-
formation was provided about how the se-
quence was generated. The number ran-
domised was small and there is a risk that
it was not balanced (14 versus 19)
Allocation concealment (selection bias) Unclear risk Quote: “… patients were randomly as-
signed to 3 groups by individuals not in-
volved in the study”
Comment: pg 1070, col 1, para 3
There is no information about allocation
concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “… double-blind… ” “... Placebo
(lactose) in unlabelled capsules”
Comment: pg 1069, abstract: methods, pg
1070 methods
Details of blinding not clear within the
paper and it does not detail whether the
placebo (and antibiotic) medications were
given on the same dosing schedule with
medication in an identical form
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Study participants and personnel
were blind during the duration of the study.
Randomisation codes were revealed to re-
searchers after recruitment,data collection,
and data entry”
Comment: details of blinding not clear
within the paper and it is not clear whether
the oral steroids and antibiotic medications
were given on the same dosing schedule and
were an identical form, which could com-
promise blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: only 7/47 patients dropped out
of the study (14.9%) but all were from the
placebo group 7/19 (36.8%). This is an im-
balance in drop-out rate and the reasons
for drop-out include “unsatisfactory ther-
apeutic effects”, “withdrawal of consent”
and “serious adverse events (asthma attack)
”. Patients who dropped out were still in-
cluded in the analysis using the last ob-
served carried forward. This may have had
an effect on the overall results and no sen-
sitivity analysis appears to have been com-
pleted to identify the impact
Selective reporting (reporting bias) Unclear risk Comment: all outcomes in the methods
section were reported in the full paper,
although many of them were presented
graphically, without providing values at key
time periods. The data were not reported
in a way that is sufficient to be included in
the meta-analysis of the review
The protocol document was available
(NCT00480298) and the outcomes appear
to be consistent between the protocol and
the paper
Other bias Unclear risk Comment: details of the scales used tomea-
sure symptoms were not provided in the
paper and there is no information on vali-
dation of the outcomes
There was an imbalance in the num-
ber of participants with “allergy” (oral
steroids: 35.7; placebo: 57.9%; antibiotics:
14.3%) and “aspirin intolerant” in the base-
line characteristics (oral steroids: 14.3%;
placebo: 26.3%; antibiotics: 7.1%). This
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was not a statistical difference between the
groups due to the study size being small.
A sensitivity analysis was completed by the
study authors to determine if this affected
the results
CRS: chronic rhinosinusitis
CT: computerised tomography
ENT: ear, nose and throat
EPOS: European Position Paper on Rhinosinusitis and Nasal Polyps 2012
F: female
INCS: intranasal corticosteroids
M: male
MFNS: mometasone furoate nasal spray
MRI: magnetic resonance imaging
RCT: randomised controlled trial
RSOM-31: Rhinosinusitis Outcome Measures-31
SD: standard deviation
SEM: standard error of the mean
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alobid 2005 INTERVENTION: oral steroids versus surgery
Blomqvist 2001 INTERVENTION: surgery
Blomqvist 2009 INTERVENTION: combined medical and surgical treatment
Bonfils 1998 STUDY DESIGN: not randomised
Bonfils 2003 STUDY DESIGN: not randomised
Bonfils 2006 STUDY DESIGN: not randomised
Bülbül 2013 INTERVENTION: both arms of the study received intranasal steroids
Chi Chan 1996 STUDY DESIGN: not randomised
Damm 1999 INTERVENTION: oral steroid (12 days) + INCS versus oral steroid (20 days) + INCS
Grammer 2013 STUDY DESIGN: review of previous oral steroids trials
Hessler 2007 STUDY DESIGN: not randomised
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Jankowski 2003a STUDY DESIGN: not randomised
Jankowski 2003b STUDY DESIGN: not randomised
Kroflic 2006 INTERVENTION: endoscopic polypectomy with ethmoidectomy
Lildholdt 1988 INTERVENTION: surgical removal versus systemic corticosteroids
Lildholdt 1989 INTERVENTION: surgical polypectomy followed by continuous topical steroid treatment versus a single dose
of depot steroid
NCT01676415 INTERVENTION: oral steroid versus intranasal steroids; both arms of the study received antibiotics
Ongoing study
Nores 2003 STUDY DESIGN: not randomised
Ozturk 2011 INTERVENTION: oral steroids versus placebo; all patients in both arms received antibiotics
Ragab 2006 INTERVENTION: medical versus surgical treatment
Rasp 1997 STUDY DESIGN: not randomised
Rasp 2000 STUDY DESIGN: not randomised
Remer 2005 STUDY DESIGN: not randomised
Reychler 2015 INTERVENTION: oral steroid versus INCS; duration of follow-up less than 3 months
Rupa 2010 POPULATION: allergic fungal sinusitis
Sieskiewicz 2006 STUDY DESIGN: surgical outcomes paper
Sousa 2009 STUDY DESIGN: not randomised
Stevens 2001 STUDY DESIGN: not randomised
Tuncer 2003 STUDY DESIGN: not randomised
van Camp 1994 STUDY DESIGN: not randomised
INCS: intranasal corticosteroids
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Chi 2011
Trial name or title ChiCTRTRC11001323: Research on clinical efficacy of oral glucocorticoid in the treatment of eosinophilic
nasal polyps and non-eosinophilic nasal polyps
Methods Randomised, parallel-group, controlled trial
Participants Chronic sinusitis with nasal polyps
Interventions Oral prednisolone tablets versus placebo
Outcomes VAS score, Lanza-Kennedy nasal endoscopy score
Starting date January 2011
Contact information Ming Zeng, Department of Otorhinolaryngology Head and Neck Surgery, Tongji Hospital of Tongji Medical
College of
Huazhong University of Science and Technology, 430030
Email: zmsx77@163.com
Notes No response from study authors
NCT00841802
Trial name or title NCT00841802: Chronic rhinosinusitis with or without nasal polyps steroid study
Methods Open-label, parallel-group randomised controlled trial
Participants Diagnosis of chronic rhinosinusitis with or without nasal polyps and undergoing sinonasal surgery for this
condition
No diagnosis of CRS and NP and undergoing nasal surgery (septoplasty/rhinoplasty, nasal fracture repair,
etc.)
Interventions Prednisone versus no intervention
Outcomes Alterations of inflammatory cells, levels of key antibodies and cytokines, and expression of key epithelial genes
Starting date February 2009
Contact information Robert P Schleimer, PhD; email: rpschleimer@northwestern.edu
Kathleen E Harris, BS; email: keharris@ northwestern.edu
Notes Authors responded to enquiry to say that the study is still in the process of being completed
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Trial name or title NCT02367118: Prednisone in chronic rhinosinusitis without nasal polyps
Methods Double-blind, parallel-group randomised controlled trial
Participants Diagnosis of CRSsNP as recommended by European Position Paper on Rhinosinusitis and Nasal Polyps 2012
Interventions Prednisone (30 mg for 7 days then 15 mg for 7 days then 5 mg for 7 days) versus placebo (21 days)
Outcomes Changes in symptoms as measured by SNOT-22 questionnaire and visual analogue scale at 6 months
Change in olfactory function as measured by “Sniffin’ Sticks 12 tests” at 6 months
Change in nasal patency as measured by acoustic rhinometry and rhinomanometry at 6 months
Changes in nasal endoscopy findings as measured by Lund-Kennedy score at 6 months
Starting date June 2015
Contact information Constanza J Valdes, MD; email: cjvaldes@gmail.com
Marcela A Veloz, MD; email: marceveloz@gmail.com
Notes Authors responded to our enquiry to say that the study is still in the process of being completed
CRS: chronic rhinosinusitis
CRSsNP: chronic rhinosinusitis without nasal polyps
NP: nasal polyps
SNOT-22: Sino-Nasal Outcome Test-22
VAS: visual analogue scale
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D A T A A N D A N A L Y S E S
Comparison 1. Oral steroids versus no treatment/placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Disease-specific health-related
quality of life - no pooling (2
to 3 weeks)
2 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Severity score of RSOM 1 40 Std. Mean Difference (IV, Fixed, 95% CI) -1.24 [-1.92, -0.56]
1.2 Mini-RQLQ 1 58 Std. Mean Difference (IV, Fixed, 95% CI) -0.79 [-1.32, -0.25]
2 Disease-specific health-related
quality of life - RQLQ (3 to 6
months)
1 50 Std. Mean Difference (IV, Fixed, 95% CI) -0.59 [-1.16, -0.02]
3Disease severity (patient-reported
total symptom score)
4 Std. Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Final value (2 to 3 weeks) 3 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Change from baseline (2
to 3 weeks)
1 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Final value (3 to 6
months)
1 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.4 Change from baseline (3
to 6 months)
1 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Individual symptoms: nasal
obstruction (final value)
1 22 Mean Difference (IV, Fixed, 95% CI) -4.5 [-6.42, -2.58]
5 Individual symptoms: nasal
obstruction (change from
baseline)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 Change from baseline (2
to 3 weeks)
1 114 Mean Difference (IV, Fixed, 95% CI) -38.02 [-48.16, -27.
88]
5.2 Change from baseline (3
to 6 months)
1 114 Mean Difference (IV, Fixed, 95% CI) 0.90 [-8.97, 10.77]
6 Individual symptoms: nasal
discharge (final value)
1 22 Mean Difference (IV, Fixed, 95% CI) -4.7 [-6.79, -2.61]
7 Individual symptoms: nasal
discharge (change from
baseline)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 2 to 3 weeks 1 114 Mean Difference (IV, Fixed, 95% CI) -55.57 [-69.23, -41.
91]
7.2 3 to 6 months 1 114 Mean Difference (IV, Fixed, 95% CI) -1.83 [-13.46, 9.81]
8 Individual symptoms: facial
pressure (final value)
1 22 Mean Difference (IV, Fixed, 95% CI) -3.7 [-6.02, -1.38]
9 Individual symptoms: facial
pressure (change from baseline)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 2 to 3 weeks 1 114 Mean Difference (IV, Fixed, 95% CI) -30.66 [-46.28, -15.
04]
9.2 3 to 6 months 1 114 Mean Difference (IV, Fixed, 95% CI) 0.60 [-12.56, 13.76]
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10 Individual symptoms: loss of
sense of smell (final value)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 2 to 3 weeks 2 80 Mean Difference (IV, Fixed, 95% CI) -2.79 [-4.11, -1.47]
10.2 3 to 6 months 1 50 Mean Difference (IV, Fixed, 95% CI) -1.20 [-2.68, 0.28]
11 Individual symptoms: loss of
sense of smell (change from
baseline)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
11.1 2 to 3 weeks (after
treatment)
1 114 Mean Difference (IV, Fixed, 95% CI) -44.35 [-57.31, -31.
39]
11.2 3 to 6 months 1 114 Mean Difference (IV, Fixed, 95% CI) -15.05 [-29.69, -0.
41]
12 Adverse events - significant
mood disturbance
1 40 Risk Ratio (M-H, Fixed, 95% CI) 2.5 [0.55, 11.41]
13 Adverse events - gastrointestinal
disturbance
3 187 Risk Ratio (M-H, Fixed, 95% CI) 3.45 [1.11, 10.78]
14 Adverse events - insomnia 3 187 Risk Ratio (M-H, Fixed, 95% CI) 3.63 [1.10, 11.95]
15 Endoscopy score - nasal polyps
(final value)
4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
15.1 2 to 3 weeks 4 253 Mean Difference (IV, Fixed, 95% CI) -0.76 [-0.92, -0.61]
15.2 3 to 6 months 1 50 Mean Difference (IV, Fixed, 95% CI) -0.25 [-0.62, 0.12]
16 Endoscopy score - nasal polyps
score (change from baseline)
2 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
16.1 2 to 3 weeks 2 146 Std. Mean Difference (IV, Fixed, 95% CI) -1.77 [-2.16, -1.38]
16.2 3 to 6 months 1 114 Std. Mean Difference (IV, Fixed, 95% CI) -0.52 [-0.90, -0.14]
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Analysis 1.1. Comparison 1 Oral steroids versus no treatment/placebo, Outcome 1 Disease-specific health-
related quality of life - no pooling (2 to 3 weeks).
Review: Short-course oral steroids alone for chronic rhinosinusitis
Comparison: 1 Oral steroids versus no treatment/placebo
Outcome: 1 Disease-specific health-related quality of life - no pooling (2 to 3 weeks)
Study or subgroup Oral steroids Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Severity score of RSOM
Hissaria 2006 20 0.868 (0.5858) 20 1.73 (0.7647) 100.0 % -1.24 [ -1.92, -0.56 ]
Subtotal (95% CI) 20 20 100.0 % -1.24 [ -1.92, -0.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.56 (P = 0.00036)
2 Mini-RQLQ
Vaidyanathan 2011 29 0.75 (1.091) 29 1.73 (1.354) 100.0 % -0.79 [ -1.32, -0.25 ]
Subtotal (95% CI) 29 29 100.0 % -0.79 [ -1.32, -0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.88 (P = 0.0040)
Test for subgroup differences: Chi2 = 1.06, df = 1 (P = 0.30), I2 =5%
-4 -2 0 2 4
Favours oral steroids Favours placebo
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Analysis 1.2. Comparison 1 Oral steroids versus no treatment/placebo, Outcome 2 Disease-specific health-
related quality of life - RQLQ (3 to 6 months).
Review: Short-course oral steroids alone for chronic rhinosinusitis
Comparison: 1 Oral steroids versus no treatment/placebo
Outcome: 2 Disease-specific health-related quality of life - RQLQ (3 to 6 months)
Study or subgroup Oral steroids Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Vaidyanathan 2011 26 0.66 (0.5199) 24 1.08 (0.8525) 100.0 % -0.59 [ -1.16, -0.02 ]
Total (95% CI) 26 24 100.0 % -0.59 [ -1.16, -0.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.04 (P = 0.041)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours oral steroids Favours placebo
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Analysis 1.3. Comparison 1 Oral steroids versus no treatment/placebo, Outcome 3 Disease severity
(patient-reported total symptom score).
Review: Short-course oral steroids alone for chronic rhinosinusitis
Comparison: 1 Oral steroids versus no treatment/placebo
Outcome: 3 Disease severity (patient-reported total symptom score)
Study or subgroup Oral steroids Placebo
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Final value (2 to 3 weeks)
Ecevit 2015 (1) 10 10.6 (5.01) 12 26.5 (5.69) -2.84 [ -4.08, -1.59 ]
Hissaria 2006 (2) 20 0.91 (0.7603) 20 2.3 (0.9391) -1.59 [ -2.31, -0.87 ]
Vaidyanathan 2011 (3) 29 1.03 (1.6562) 28 3.22 (3.5073) -0.79 [ -1.33, -0.25 ]
2 Change from baseline (2 to 3 weeks)
Kirtsreesakul 2012 (4) 67 -62.989 (19.304) 47 -21.11 (16.596) -2.28 [ -2.76, -1.80 ]
3 Final value (3 to 6 months)
Vaidyanathan 2011 (5) 27 1 (1.0617) 24 1.54 (1.3972) -0.43 [ -0.99, 0.12 ]
4 Change from baseline (3 to 6 months)
Kirtsreesakul 2012 (6) 67 -68.512 (18.623) 47 -64.67 (15.191) -0.22 [ -0.59, 0.15 ]
-4 -2 0 2 4
Favours oral steroids Favours placebo
(1) Measured 4 EPOS symptoms: nasal obstruction, nasal discharge, sense of smell and pressure over the sinuses
(2) 3 EPOS domains covered (nasal subscale of RSOM-31): congestion, rhinorrhoea, sneezing, hyposmia, postnasal discharge and thick nasal debris
(3) 2 EPOS domains covered: sum of scores nasal discharge, nasal blockage, nasal itch and sneezing
(4) 4 domains of EPOS covered: blocked nose, rhinorrhoea, hyposmia and sinonasal pain
(5) 2 EPOS domains covered: sum of scores nasal discharge, nasal blockage, nasal itch and sneezing
(6) 4 domains of EPOS covered: blocked nose, rhinorrhoea, hyposmia and sinonasal pain
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Analysis 1.4. Comparison 1 Oral steroids versus no treatment/placebo, Outcome 4 Individual symptoms:
nasal obstruction (final value).
Review: Short-course oral steroids alone for chronic rhinosinusitis
Comparison: 1 Oral steroids versus no treatment/placebo
Outcome: 4 Individual symptoms: nasal obstruction (final value)
Study or subgroup Oral steroids Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ecevit 2015 10 2.6 (2.2) 12 7.1 (2.4) 100.0 % -4.50 [ -6.42, -2.58 ]
Total (95% CI) 10 12 100.0 % -4.50 [ -6.42, -2.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.58 (P < 0.00001)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours oral steroids Favours placebo
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Analysis 1.5. Comparison 1 Oral steroids versus no treatment/placebo, Outcome 5 Individual symptoms:
nasal obstruction (change from baseline).
Review: Short-course oral steroids alone for chronic rhinosinusitis
Comparison: 1 Oral steroids versus no treatment/placebo
Outcome: 5 Individual symptoms: nasal obstruction (change from baseline)
Study or subgroup Oral steroids Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Change from baseline (2 to 3 weeks)
Kirtsreesakul 2012 67 -57.79 (27.8302) 47 -19.77 (26.7371) 100.0 % -38.02 [ -48.16, -27.88 ]
Subtotal (95% CI) 67 47 100.0 % -38.02 [ -48.16, -27.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.35 (P < 0.00001)
2 Change from baseline (3 to 6 months)
Kirtsreesakul 2012 67 -65.42 (29.5491) 47 -66.32 (24.0633) 100.0 % 0.90 [ -8.97, 10.77 ]
Subtotal (95% CI) 67 47 100.0 % 0.90 [ -8.97, 10.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Chi2 = 29.06, df = 1 (P = 0.00), I2 =97%
-100 -50 0 50 100
Favours oral steroids Favours placebo
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Analysis 1.6. Comparison 1 Oral steroids versus no treatment/placebo, Outcome 6 Individual symptoms:
nasal discharge (final value).
Review: Short-course oral steroids alone for chronic rhinosinusitis
Comparison: 1 Oral steroids versus no treatment/placebo
Outcome: 6 Individual symptoms: nasal discharge (final value)
Study or subgroup Oral steroids Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ecevit 2015 10 1 (1.7) 12 5.7 (3.2) 100.0 % -4.70 [ -6.79, -2.61 ]
Total (95% CI) 10 12 100.0 % -4.70 [ -6.79, -2.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.40 (P = 0.000011)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours oral steroids Favours placebo
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Analysis 1.7. Comparison 1 Oral steroids versus no treatment/placebo, Outcome 7 Individual symptoms:
nasal discharge (change from baseline).
Review: Short-course oral steroids alone for chronic rhinosinusitis
Comparison: 1 Oral steroids versus no treatment/placebo
Outcome: 7 Individual symptoms: nasal discharge (change from baseline)
Study or subgroup Oral steroids Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 2 to 3 weeks
Kirtsreesakul 2012 67 -75.84 (34.2148) 47 -20.27 (38.2546) 100.0 % -55.57 [ -69.23, -41.91 ]
Subtotal (95% CI) 67 47 100.0 % -55.57 [ -69.23, -41.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.97 (P < 0.00001)
2 3 to 6 months
Kirtsreesakul 2012 67 -76.06 (36.9159) 47 -74.23 (26.4628) 100.0 % -1.83 [ -13.46, 9.81 ]
Subtotal (95% CI) 67 47 100.0 % -1.83 [ -13.46, 9.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Chi2 = 34.44, df = 1 (P = 0.00), I2 =97%
-100 -50 0 50 100
Favours oral steroids Favours placebo
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Analysis 1.8. Comparison 1 Oral steroids versus no treatment/placebo, Outcome 8 Individual symptoms:
facial pressure (final value).
Review: Short-course oral steroids alone for chronic rhinosinusitis
Comparison: 1 Oral steroids versus no treatment/placebo
Outcome: 8 Individual symptoms: facial pressure (final value)
Study or subgroup Oral steroids Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ecevit 2015 10 1.5 (2.1) 12 5.2 (3.4) 100.0 % -3.70 [ -6.02, -1.38 ]
Total (95% CI) 10 12 100.0 % -3.70 [ -6.02, -1.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.12 (P = 0.0018)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours oral steroids Favours placebo
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Analysis 1.9. Comparison 1 Oral steroids versus no treatment/placebo, Outcome 9 Individual symptoms:
facial pressure (change from baseline).
Review: Short-course oral steroids alone for chronic rhinosinusitis
Comparison: 1 Oral steroids versus no treatment/placebo
Outcome: 9 Individual symptoms: facial pressure (change from baseline)
Study or subgroup Oral steroids Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 2 to 3 weeks
Kirtsreesakul 2012 67 -60.63 (48.8666) 47 -29.97 (36.1979) 100.0 % -30.66 [ -46.28, -15.04 ]
Subtotal (95% CI) 67 47 100.0 % -30.66 [ -46.28, -15.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.85 (P = 0.00012)
2 3 to 6 months
Kirtsreesakul 2012 67 -72.67 (44.8557) 47 -73.27 (26.5999) 100.0 % 0.60 [ -12.56, 13.76 ]
Subtotal (95% CI) 67 47 100.0 % 0.60 [ -12.56, 13.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Chi2 = 9.00, df = 1 (P = 0.00), I2 =89%
-100 -50 0 50 100
Favours oral steroids Favours placebo
71Short-course oral steroids alone for chronic rhinosinusitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.10. Comparison 1 Oral steroids versus no treatment/placebo, Outcome 10 Individual symptoms:
loss of sense of smell (final value).
Review: Short-course oral steroids alone for chronic rhinosinusitis
Comparison: 1 Oral steroids versus no treatment/placebo
Outcome: 10 Individual symptoms: loss of sense of smell (final value)
Study or subgroup Oral steroids Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 2 to 3 weeks
Ecevit 2015 10 5.5 (3.6) 12 8.5 (2.2) 26.7 % -3.00 [ -5.55, -0.45 ]
Vaidyanathan 2011 29 2.75 (2.41) 29 5.46 (3.49) 73.3 % -2.71 [ -4.25, -1.17 ]
Subtotal (95% CI) 39 41 100.0 % -2.79 [ -4.11, -1.47 ]
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 4.14 (P = 0.000035)
2 3 to 6 months
Vaidyanathan 2011 26 2.93 (2.33) 24 4.13 (2.93) 100.0 % -1.20 [ -2.68, 0.28 ]
Subtotal (95% CI) 26 24 100.0 % -1.20 [ -2.68, 0.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
Test for subgroup differences: Chi2 = 2.47, df = 1 (P = 0.12), I2 =59%
-10 -5 0 5 10
Favours oral steroids Favours placebo
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Analysis 1.11. Comparison 1 Oral steroids versus no treatment/placebo, Outcome 11 Individual symptoms:
loss of sense of smell (change from baseline).
Review: Short-course oral steroids alone for chronic rhinosinusitis
Comparison: 1 Oral steroids versus no treatment/placebo
Outcome: 11 Individual symptoms: loss of sense of smell (change from baseline)
Study or subgroup Oral steroids Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 2 to 3 weeks (after treatment)
Kirtsreesakul 2012 67 -57.69 (40.2719) 47 -13.34 (30.302) 100.0 % -44.35 [ -57.31, -31.39 ]
Subtotal (95% CI) 67 47 100.0 % -44.35 [ -57.31, -31.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.71 (P < 0.00001)
2 3 to 6 months
Kirtsreesakul 2012 67 -59.9 (36.1793) 47 -44.85 (41.271) 100.0 % -15.05 [ -29.69, -0.41 ]
Subtotal (95% CI) 67 47 100.0 % -15.05 [ -29.69, -0.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.02 (P = 0.044)
Test for subgroup differences: Chi2 = 8.63, df = 1 (P = 0.00), I2 =88%
-50 -25 0 25 50
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Analysis 1.12. Comparison 1 Oral steroids versus no treatment/placebo, Outcome 12 Adverse events -
significant mood disturbance.
Review: Short-course oral steroids alone for chronic rhinosinusitis
Comparison: 1 Oral steroids versus no treatment/placebo
Outcome: 12 Adverse events - significant mood disturbance
Study or subgroup Oral steroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hissaria 2006 5/20 2/20 100.0 % 2.50 [ 0.55, 11.41 ]
Total (95% CI) 20 20 100.0 % 2.50 [ 0.55, 11.41 ]
Total events: 5 (Oral steroids), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours oral steroids Favours placebo
Analysis 1.13. Comparison 1 Oral steroids versus no treatment/placebo, Outcome 13 Adverse events -
gastrointestinal disturbance.
Review: Short-course oral steroids alone for chronic rhinosinusitis
Comparison: 1 Oral steroids versus no treatment/placebo
Outcome: 13 Adverse events - gastrointestinal disturbance
Study or subgroup Oral steroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hissaria 2006 2/20 1/20 25.8 % 2.00 [ 0.20, 20.33 ]
Kirtsreesakul 2012 11/67 1/47 30.4 % 7.72 [ 1.03, 57.76 ]
Van Zele 2010 2/14 2/19 43.8 % 1.36 [ 0.22, 8.50 ]
Total (95% CI) 101 86 100.0 % 3.45 [ 1.11, 10.78 ]
Total events: 15 (Oral steroids), 4 (Placebo)
Heterogeneity: Chi2 = 1.82, df = 2 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 2.13 (P = 0.033)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours oral steroids Favours placebo
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Analysis 1.14. Comparison 1 Oral steroids versus no treatment/placebo, Outcome 14 Adverse events -
insomnia.
Review: Short-course oral steroids alone for chronic rhinosinusitis
Comparison: 1 Oral steroids versus no treatment/placebo
Outcome: 14 Adverse events - insomnia
Study or subgroup Oral steroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hissaria 2006 8/20 2/20 66.3 % 4.00 [ 0.97, 16.55 ]
Kirtsreesakul 2012 1/67 0/47 19.4 % 2.12 [ 0.09, 50.88 ]
Van Zele 2010 1/14 0/19 14.2 % 4.00 [ 0.17, 91.48 ]
Total (95% CI) 101 86 100.0 % 3.63 [ 1.10, 11.95 ]
Total events: 10 (Oral steroids), 2 (Placebo)
Heterogeneity: Chi2 = 0.13, df = 2 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 2.12 (P = 0.034)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours oral steroids Favours placebo
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Analysis 1.15. Comparison 1 Oral steroids versus no treatment/placebo, Outcome 15 Endoscopy score -
nasal polyps (final value).
Review: Short-course oral steroids alone for chronic rhinosinusitis
Comparison: 1 Oral steroids versus no treatment/placebo
Outcome: 15 Endoscopy score - nasal polyps (final value)
Study or subgroup Oral steroids
Placebo/no
treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 2 to 3 weeks
Alobid 2014 67 2.12 (0.6) 22 2.81 (0.7) 22.4 % -0.69 [ -1.02, -0.36 ]
Benitez 2006 63 2.1 (0.7937) 21 2.8 (0.4583) 31.0 % -0.70 [ -0.98, -0.42 ]
Ecevit 2015 10 2.2 (0.422) 12 2.64 (0.505) 15.9 % -0.44 [ -0.82, -0.05 ]
Vaidyanathan 2011 29 1.3 (0.6572) 29 2.35 (0.3943) 30.6 % -1.05 [ -1.33, -0.77 ]
Subtotal (95% CI) 169 84 100.0 % -0.76 [ -0.92, -0.61 ]
Heterogeneity: Chi2 = 7.20, df = 3 (P = 0.07); I2 =58%
Test for overall effect: Z = 9.69 (P < 0.00001)
2 3 to 6 months
Vaidyanathan 2011 26 1.4 (0.7427) 24 1.65 (0.592) 100.0 % -0.25 [ -0.62, 0.12 ]
Subtotal (95% CI) 26 24 100.0 % -0.25 [ -0.62, 0.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Chi2 = 6.26, df = 1 (P = 0.01), I2 =84%
-2 -1 0 1 2
Favours oral steroids Favours control
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Analysis 1.16. Comparison 1 Oral steroids versus no treatment/placebo, Outcome 16 Endoscopy score -
nasal polyps score (change from baseline).
Review: Short-course oral steroids alone for chronic rhinosinusitis
Comparison: 1 Oral steroids versus no treatment/placebo
Outcome: 16 Endoscopy score - nasal polyps score (change from baseline)
Study or subgroup Oral steroids
Placebo/no
treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 2 to 3 weeks
Hissaria 2006 15 -48.498 (25.7631) 17 -7.3 (13.2723) 20.1 % -2.00 [ -2.87, -1.13 ]
Kirtsreesakul 2012 67 -44.653 (32.969) 47 -0.76 (5.237) 79.9 % -1.71 [ -2.14, -1.27 ]
Subtotal (95% CI) 82 64 100.0 % -1.77 [ -2.16, -1.38 ]
Heterogeneity: Chi2 = 0.34, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 8.88 (P < 0.00001)
2 3 to 6 months
Kirtsreesakul 2012 67 -46.458 (32.3976) 47 -29.38 (32.3724) 100.0 % -0.52 [ -0.90, -0.14 ]
Subtotal (95% CI) 67 47 100.0 % -0.52 [ -0.90, -0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.71 (P = 0.0068)
Test for subgroup differences: Chi2 = 20.05, df = 1 (P = 0.00), I2 =95%
-4 -2 0 2 4
Favours oral steroids Favours control
A D D I T I O N A L T A B L E S
Table 1. Summary of the most commonly reported side effects of systemic steroids
System Adverse events Notes
Musculoskeletal Osteoporosis Largely limited to long-term use
Significantly increased risk of fractures with prolonged use
Osteonecrosis Rare, appears to be dose-dependent
Endocrine Hyperglycaemia Common; dose-dependent, usually reversible
Cardiovascular Hypertension Common; dose-dependent, usually reversible
Dermatological Striae, bruising Dose-dependent; occurs after > 1 month usage
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Table 1. Summary of the most commonly reported side effects of systemic steroids (Continued)
Ophthalmological Cataracts Irreversible; largely related to long-term usage
Glaucoma High risk with pre-existing disease
Gastrointestinal tract Peptic ulceration Increased risk largely due to concomitant NSAIDs
Psychological Psychosis Common; increased risk with dosages > 40 mg/day
References: Da Silva 2006; Naber 1996; Stanbury 1998
NSAIDs: non-steroidal anti-inflammatory drugs
A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL Ovid MEDLINE
#1 MeSH descriptor: [Sinusitis] explode all trees
#2 MeSH descriptor: [Rhinitis] this term only
#3 MeSH descriptor: [Rhinitis, Atrophic] this term only
#4 MeSH descriptor: [Rhinitis, Vasomotor] this term only
#5 MeSH descriptor: [Paranasal Sinus Diseases] this term only
#6 MeSH descriptor: [Paranasal Sinuses] explode all trees
#7 rhinosinusitis or nasosinusitis or pansinusitis or ethmoiditis or
sphenoiditis
#8 kartagener* near syndrome*
#9 inflamm* near sinus*
#10 (maxilla* or frontal*) near sinus*
#11 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
#12 MeSH descriptor: [Chronic Disease] explode all trees
#13 MeSH descriptor: [Recurrence] explode all trees
#14 chronic or persis* or recurrent*
#15 #12 or #13 or #14
#16 #11 and #15
#17 CRSsNP
#18 (sinusitis or rhinitis) near (chronic or persis* or recurrent*)
#19 #16 or #17 or #18
#20 MeSH descriptor: [Nasal Polyps] explode all trees
#21 MeSH descriptor: [Nose] explode all trees
#22 MeSH descriptor: [Nose Diseases] explode all trees
#23 #21 or #22
1 exp Sinusitis/
2 paranasal sinus diseases/ or rhinitis/ or rhinitis, atrophic/ or
rhinitis, vasomotor/
3 exp Paranasal Sinuses/
4 (rhinosinusitis or nasosinusitis or pansinusitis or ethmoiditis or
sphenoiditis).ab,ti
5 (kartagener* adj3 syndrome*).ab,ti.
6 (inflamm* adj5 sinus*).ab,ti.
7 ((maxilla* or frontal*) adj3 sinus*).ab,ti.
8 1 or 2 or 3 or 4 or 5 or 6 or 7
9 exp chronic disease/
10 exp Recurrence/
11 (chronic or persis* or recurrent*).ab,ti.
12 9 or 10 or 11
13 8 and 12
14 CRSsNP.ab,ti.
15 ((sinusitis or rhinitis) adj3 (chronic or persis* or recurrent*)).
ab,ti
16 13 or 14 or 15
17 exp Nasal Polyps/
18 exp Nose/ or exp Nose Diseases/
19 exp Polyps/
20 18 and 19
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(Continued)
#24 MeSH descriptor: [Polyps] explode all trees
#25 #23 and #24
#26 (nose or nasal or rhino* or rhinitis or sinus* or sinonasal) near
(papilloma* or polyp*)
#27 rhinopolyp* or CRSwNP
#28 #19 or #20 or #25 or #26 or #27
#29 MeSH descriptor: [Steroids] explode all trees
#30 MeSH descriptor: [Adrenal Cortex Hormones] explode all
trees
#31 MeSH descriptor: [Glucocorticoids] explode all trees
#32 MeSH descriptor: [Anti-Inflammatory Agents] explode all
trees
#33 MeSH descriptor: [Anti-Inflammatory Agents, Non-
Steroidal] explode all trees
#34 #32 not #33
#35 steroid* or glucocorticoid* or corticosteroid* or glucosteroid*
or cyclocosteroid*
#36 beclomethasone or beclometasone or beclamet or beclocort
or becotide
#37 betamethasone or betadexamethasone or flubenisolone or ce-
leston* or cellestoderm or betnelan or oradexon
#38 dexamethasoneor dexameth or dexone or dexametasone or
decadron or dexasone or hexadecadron or hexadrol or methylflu-
orprednisolone or millicorten
#39 flunisolide or fluticasone or hydrocortisone or cortisol or cor-
tifair or cortril or hyrocortone or cortef or epicortisol or efcortesol
or Cortisone
#40 methylprednisolone or medrol or metripred or urbason
#41 mometasone or prednisolone or precortisyl or deltacortril or
deltastab or prednesol or deltasone or prednisone or cortan or
liquid next pred or meticorten
#42 paramethasone or triamcinolone or aristocort or volon or
atolone or kenacort or orasone or panasol or prednicen
#43 corticoid* or betamethason* or betamethasone or hydrocorti-
son* or celesto* or dexamethason* or hexadecadrol or budesonid*
or horacort or pulmicort or rhinocort or methylfluorprednisolone
or flunisolid* or nasalide or fluticason* or flonase or flounce or
mometason* or nasonex or triamclinolon* or nasacort or tri next
nasal or aristocort or Ciclesonide
#44 #29 or #30 or #31 or #34 or #35 or #36 or #37 or #38 or #
39 or #40 or #41 or #42 or #43
#45 #28 and #44
21 ((nose or nasal or rhino* or rhinitis or sinus* or sinonasal) adj3
(papilloma* or polyp*)).ab,ti
22 (rhinopolyp* or CRSwNP).ab,ti.
23 16 or 17 or 20 or 21 or 22
24 exp Steroids/
25 exp Adrenal Cortex Hormones/
26 exp Glucocorticoids/
27 exp Anti-Inflammatory Agents/
28 exp Anti-Inflammatory Agents, Non-Steroidal/
29 27 not 28
30 (steroid* or glucocorticoid* or corticosteroid* or glucos-
teroid* or cyclocosteroid* orbeclomethasone or beclometasone or
beclamet or beclocort or becotide or betamethasone or betadexam-
ethasone or flubenisolone or celeston* or cellestoderm or betnelan
or oradexon or dexamethasone or dexameth or dexone or dexam-
etasone or decadron or dexasone or hexadecadron or hexadrol or
methylfluorprednisolone or millicorten or flunisolide or fluticas-
one or hydrocortisone or cortisol or cortifair or cortril or hyrocor-
tone or cortef or epicortisol or efcortesol or Cortisone or methyl-
prednisolone or medrol or metripred or urbason or mometasone
or prednisolone or precortisyl or deltacortril or deltastab or pred-
nesol or deltasone or prednisone or cortan or liquid next pred
or meticorten or paramethasone or triamcinolone or aristocort or
volon or atolone or kenacort or orasone or panasol or prednicen)
.ab,ti
31 (corticoid* or betamethason* or betamethasone or hydrocorti-
son* or celesto* or dexamethason* or hexadecadrol or budesonid*
or horacort or pulmicort or rhinocort or methylfluorprednisolone
or flunisolid* or nasalide or fluticason* or flonase or flounce or
mometason* or nasonex or triamclinolon* or nasacort or (tri adj3
nasal) or aristocort or Ciclesonide).ab,ti
32 24 or 25 or 26 or 29 or 30 or 31
33 23 and 32
Ovid EMBASE Trial registries (via CRS)
1 exp sinusitis/ or paranasal sinus disease/
2 atrophic rhinitis/ or chronic rhinitis/ or rhinosinusitis/ or vaso-
motor rhinitis/
3 exp paranasal sinus/
4 (rhinosinusitis or nasosinusitis or pansinusitis or ethmoiditis or
ClinicalTrials.gov
Condition: rhinitis OR sinusitis OR rhinosinusitis OR (nose
AND polyp*) OR (nasal AND polyp*) OR CRSsNP OR CR-
SwNP OR CRS
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(Continued)
sphenoiditis).tw
5 (kartagener* adj3 syndrome*).tw.
6 (inflamm* adj5 sinus*).tw.
7 ((maxilla* or frontal*) adj3 sinus*).tw.
8 1 or 2 or 3 or 4 or 5 or 6 or 7
9 exp chronic disease/
10 exp recurrent disease/
11 (chronic or persis* or recurrent*).tw.
12 9 or 10 or 11
13 8 and 12
14 CRSsNP.tw.
15 ((sinusitis or rhinitis) adj3 (chronic or persis* or recurrent*)).
tw
16 13 or 14 or 15
17 exp nose polyp/
18 exp nose disease/ or exp nose/
19 exp polyp/
20 18 and 19
21 ((nose or nasal or rhino* or rhinitis or sinus* or sinonasal) adj3
(papilloma* or polyp*)).tw
22 (rhinopolyp* or CRSwNP).tw.
23 16 or 17 or 20 or 21 or 22
24 exp *corticosteroid/
25 exp steroid/
26 exp antiinflammatory agent/
27 exp nonsteroid antiinflammatory agent/
28 26 not 27
29 (steroid* or glucocorticoid* or corticosteroid* or glucos-
teroid* or cyclocosteroid* or beclomethasone or beclometasone or
beclamet or beclocort or becotide or betamethasone or betadexam-
ethasone or flubenisolone or celeston* or cellestoderm or betnelan
or oradexon or dexamethasone or dexameth or dexone or dexam-
etasone or decadron or dexasone or hexadecadron or hexadrol or
methylfluorprednisolone or millicorten or flunisolide or fluticas-
one or hydrocortisone or cortisol or cortifair or cortril or hyrocor-
tone or cortef or epicortisol or efcortesol or Cortisone or methyl-
prednisolone or medrol or metripred or urbason or mometasone
or prednisolone or precortisyl or deltacortril or deltastab or pred-
nesol or deltasone or prednisone or cortan or liquid next pred
or meticorten or paramethasone or triamcinolone or aristocort or
volon or atolone or kenacort or orasone or panasol or prednicen)
.tw
30 24 or 28 or 29
31 23 and 30
ICTRP
Title: rhinitis OR sinusitis OR rhinosinusitis OR CRSsNP OR
CRSwNP OR CR
OR
All: (nose AND polyp*) OR (nasal AND polyp*)
NB These searches were run from 1 March 2015 to 11 August 2015,
when these terms were last searched to populate the Cochrane ENT
trials register in CRS
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Appendix 2. Data extraction form
REF ID: Study title:
Date of extraction: Extracted by:
General comments/notes (internal for discussion):
Flow chart of trial
Group A (Intervention) Group B (Comparison)
No. of people screened
No. of participants randomised - all
No. randomised to each group
No. receiving treatment as allocated
No. not receiving treatment as allocated
- Reason 1
- Reason 2
No. dropped out
(no follow-up data for any outcome avail-
able)
No. excluded from analysis1 (for all out-
comes)
- Reason 1
- Reason 2
1This should be the people who received the treatment and were therefore not considered ’drop-outs’ but were excluded from all
analyses (e.g. because the data could not be interpreted or the outcome was not recorded for some reason)
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Information to go into ’Characteristics of included studies’ table
Methods X arm, double/single/non-blinded, [multicentre] parallel-group/
cross-over/cluster-RCT, with x duration of treatment and x dura-
tion of follow-up
Participants Location: country, no of sites etc.
Setting of recruitment and treatment:
Sample size:
• Number randomised: x in intervention, y in comparison
• Number completed: x in intervention, y in comparison
Participant (baseline) characteristics:
• Age:
• Gender:
• Main diagnosis: [as stated in paper]
• Polyps status: x % with polyps/no information [add info on
mean polyps score if available]
• Previous sinus surgery status: [x% with previous surgery]
• Previous courses of steroids: [add info on mean number of
courses if available]
• Other important effect modifiers, if applicable (e.g. aspirin
sensitivity, comorbidities of asthma):
Inclusion criteria: [state diagnostic criteria used for CRS, polyps
score if available]
Exclusion criteria:
Interventions Intervention (n = x): drug name, method of administration, dose
per day/frequency of administration, duration of treatment
Comparator group (n = y):
Use of additional interventions (common to both treatment arms)
:
Outcomes Outcomes of interest in the review:
Primary outcomes:
• Health-related quality of life, disease-specific
• Disease severity symptom score
• Significant adverse effects: [review specific]
Secondary outcomes:
• Health-related quality of life, generic
• [Other review specific, pre-specified adverse events]
• [Other review specific, pre-specified adverse events]
• Endoscopy (polyps size or overall score)
• CT scan
Other outcomes reported by the study:
• [List outcomes reported but not of interest to the review]
Funding sources ’No information provided’/’None declared’/State source of fund-
ing
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(Continued)
Declarations of interest ’No information provided’/’None declared’/State conflict
Notes
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Quote: “…”
Comment:
Allocation concealment (selection bias) Quote: “…”
Comment:
Blinding of participants and personnel
(performance bias)
Quote: “…”
Comment:
Blinding of outcome assessment (detection
bias)
Quote: “…”
Comment:
Incomplete outcome data (attrition bias) Quote: “…”
Comment:
Selective reporting (reporting bias) Quote: “…”
Comment:
Other bias (see section 8.15)
Insensitive/non-validated instrument?
Quote: “…”
Comment:
Other bias (see section 8.15) Quote: “…”
Comment:
Findings of study: continuous outcomes
Results (continuous data table)
Outcome Group A Group B Other summary stats/Notes
Mean SD N Mean SD N Mean difference (95% CI), P values etc.
Disease-spe-
cific HRQL
(instrument
name/range)
Time point:
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(Continued)
Generic
HRQL
(instrument
name/range)
Time point:
Symptom
score (overall)
(instrument
name/range)
Time point:
Added total -
if scores re-
ported
separately for
each symptom
(range)
Time point:
Nasal
blockage/
obstruction/
congestion
(instrument
name/range)
Nasal
discharge
(instrument
name/range)
Facial pain/
pressure
(instrument
name/range)
Smell (reduc-
tion)
(instrument
name/range)
Headache
(instrument
name/range)
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(Continued)
Cough (in
children)
(instrument
name/range)
Polyp size
(instrument
name/range)
CT score
(instrument
name/range)
Comments:
Results (dichotomous data table)
Outcome Ap-
plicable review/
intervention
Group A Group B Other summary
stats/notes
No. of people
with events
No. of people
analysed
No. of people
with events
No. of people
analysed
P values, RR
(95% CI), OR
(95% CI)
Epistaxis/nose
bleed
INCS
Saline irrigation
Local irritation
(sore throat, oral
thrush, discom-
fort)
INCS
Saline irrigation
Os-
teoporosis (min-
imum 6months)
INCS
Stunted growth
(children, mini-
mum 6 months)
INCS Can also be mea-
sured as average
height
Mood
disturbances
OCS
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(Continued)
Gastrointestinal
disturbances
(diarrhoea, nau-
sea, vom-
iting, stomach ir-
ritation)
OCS
Antibiotics
Insomnia OCS
Os-
teoporosis (min-
imum 6months)
INCS
OCS
Discomfort Saline irrigation
Suspected aller-
gic reaction (rash
or skin irritation)
Antibiotics
Anaphylaxis
or other serious
allergic reactions
such as Stevens-
Johnson
Antibiotics
Comments:
Appendix 3. EPOS 2012 diagnostic criteria
Clinical definition of rhinosinusitis in adults
Chronic rhinosinusitis, with or without nasal polyps, in adults is defined as:
• inflammation of the nose and the paranasal sinuses characterised by two or more symptoms, one of which should be either nasal
blockage/obstruction/congestion or nasal discharge (anterior/posterior nasal drip);
• ± facial pain/pressure;
• ± reduction or loss of sense of smell.
for ≥12 weeks.
This should be supported by demonstrable disease.
Either endoscopic signs of:
• nasal polyps; and/or
• mucopurulent discharge primarily from middle meatus; and/or
• oedema/mucosal obstruction primarily in middle meatus;
and/or
• CT changes:
◦ mucosal changes within the ostiomeatal complex and/or sinuses.
Clinical definition of rhinosinusitis in children
Paediatric rhinosinusitis is defined as: inflammation of the nose and the paranasal sinuses characterised by two or more symptoms, one
of which should be either nasal blockage/obstruction/congestion or nasal discharge (anterior/ posterior nasal drip):
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• ± facial pain/pressure;
• ± cough;
and either endoscopic signs of:
• nasal polyps; and/or
• mucopurulent discharge primarily from middle meatus; and/or
• oedema/mucosal obstruction primarily in middle meatus;
and/or
• CT changes:
◦ mucosal changes within the ostiomeatal complex and/ or sinuses.
Appendix 4. Nasal polyp grading scales
Grade Ecevit 2015 Lildholdt
scale: Alobid 2014; Benitez
2006; Vaidyanathan 2011
Van Zele 2010 Kirtsreesakul 2012
0 No polyps No nasal polyps No polyps No polyps
1 Mild polyposis (small polyps
not reaching the upper edge
of the inferior turbinate)
Small polyps confined to the
middle meatus
Small polyps in the middle
meatus not reaching below
the inferior border of the
middle concha
Mild polyposis (small polyps,
extending downward from
the upper nasal cavity but
not below the upper edge of
the inferior turbinate, caus-
ing only slight obstruction)
2 Moderate polyposis
(medium polyps between the
upper and lower edges of the
inferior turbinate)
Moderate sized polyps not
crossing the lower edge of the
inferior turbinate
Polyps reaching below the
lower border of the middle
turbinate
Moder-
ate polyposis (medium sized
polyps, extending downward
from the upper nasal cav-
ity and reaching between the
upper and lower edges of
the inferior turbinate, caus-
ing troublesome obstruction)
3 Severe polyposis (large polyps
reaching the lower edge of
the inferior turbinate, polyps
from posterior ethmoidal si-
nuses, or both)
Large polyps crossing the
lower edge of the inferior
turbinate
Large polyps reaching the
lower border of the inferior
turbinate or polyps medial to
the middle concha
Severe polyposis (large-sized
polyps, extending downward
from the upper nasal cavity
and reaching below the lower
edge of the inferior turbinate,
causing total or almost total
obstruction)
4 - - Large polyps causing al-
most complete congestion/
obstruction of the inferior
meatus
-
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
As part of the discussions about the use of a total symptom score we noted that many papers within the suite of reviews did not present
information for all four elements of the EPOS criteria for defining chronic rhinosinusitis (EPOS 2012). In particular, many studies
that only included patients with nasal polyps did not present information on facial pressure or pain. We made the decision that where
individual symptoms were recorded, they should be presented within the outcome of disease severity symptom score within the paper
as this information would be useful for the reader.
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